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Abstract 
 
With approximately 50% of tumours bearing mutations in the TP53 gene, the tumour 
suppressor p53 is one of the most frequently altered proteins in human cancer. In tumours 
retaining wild-type p53, other aberrations including overexpression of MDM2 may impair 
the function of the p53 pathway. MDM2 regulates p53 by inhibiting p53-mediated 
transcriptional activity and promoting its degradation. Inhibiting the MDM2-p53 interaction 
with small molecule antagonist Nutlin-3 is an attractive approach to reactivate p53 in tumours 
overexpressing MDM2. Photochemical internalisation (PCI) is a novel technology for the 
release of therapeutic macromolecules into the cytosol. The technology is based on the use of 
photosensitizers located in endocytic vesicles that upon activation by light induces release of 
the endocytosed macromolecules. In the current study, the p53
Wt
 MDM2
Ampl
 osteosarcoma 
cell line SJSA-1 was treated with a combination of Nutlin-3 and PCI of bleomycin or saporin 
to study the impact of Nutlin-3 on the p53 pathway. Treatment with PCI of bleomycin and 
Nutlin-3 resulted in increased expression of p53 and the p53 target genes MDM2, p21 and 
Bax. PCI of bleomycin in combination with Nutlin-3 also induced cell cycle arrest in the 
G1/S checkpoint, but did not have a substantial impact on the induction of apoptosis. PCI of 
bleomycin and saporin both in presence and absence of Nutlin-3 inhibited cell growth, but the 
differences were negligible. These results indicate that Nutlin-3 in the concentration given in 
this study activates p53 leading to cell cycle arrest, while the effect on apoptosis remain 
ambiguous. The current study suggests that inhibition of the p53-MDM2 interaction with 
Nutlin-3 may be a promising strategy for improving tumour response to PCI in MDM2
Ampl
 
malignancies retaining wild-type p53.  
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Abbreviations 
 
Ampl  Amplified 
APS  Ammonium persulfate 
Bax  Bcl-2-associated X protein 
BLM  Bleomycin 
BSA  Bovine serum albumin 
Cdk  Cyclin-dependent kinase 
CKI  Cyclin-dependent kinase inhibitor 
ddH2O  Double distilled water 
dH2O  Distilled water 
DMSO  Dimethyl sulfoxide 
DNA  Deoxyribonucleic acid 
DTT  Dithiotreitol 
EDTA  Ethylenediaminetetraacetic acid 
FBS  Fetal bovine serum 
IC  Internal conversion 
ISC  Intersystem crossing 
LD  Lethal dose 
MDM2 Murine double minute 2 
MTT  3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide 
Mut  Mutated 
MW  Molecular weight 
NT  No treatment 
OD  Optical density 
OSA  Osteosarcoma 
PBS  Phosphate buffered saline 
PDT  Photodynamic therapy 
PCI  Photochemical internalization 
PS  Photosensitizer 
PVDF  Polyvinylidene difluoride 
ROS  Reactive oxygen species 
SDS  Sodium dodecyl sulfate 
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SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
TdT  Terminal deoxynucleotidyl transferase 
TEMED Tetramethylethylenediamine 
TP53  Tumour protein 53 
TPCS2a Disulfonated tetraphenyl chlorine 
TPPS2a  Disulfonated tetraphenyl porphine 
TUNEL TdT-mediated dUTP Nick End Labeling 
Wt  Wild-type 
γH2AX Phosphorylated Histone H2AX 
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Aim of the study 
Despite many advances in cancer therapy there are still major challenges to overcome. Low 
specificity, dose-limiting toxicity and resistance to cytotoxic drugs are sources of therapeutic 
failure and severe side effects. New treatment regimes targeting tumours more specifically by 
exploiting their differences from normal cells hold great potential in cancer therapy.  
 Mutations of the tumour suppressor p53 are found in half of human malignancies, 
making the TP53 gene one of the most frequently mutated genes in cancer [1]. The remaining 
50% of tumours express wild-type p53 and are thus capable of activating the p53 pathway. 
However, aberrations in p53 regulation or signalling may result in inadequate tumour 
suppression. One such aberration is amplification of MDM2, the negative regulator of p53 
[2]. Mutation of p53 and MDM2 amplification is found to be largely independent making 
MDM2 an attractive target in tumours where non-functional p53 is due to overexpression of 
MDM2 protein [3]. 
 The aim of this study was to investigate what impact the MDM2 inhibitor Nutlin-3 
has on cell survival, cell cycle progression and expression of p53 and p53 downstream targets 
after PDT and PCI treatment in cell lines with different p53 and MDM2 status. The objective 
was to see if Nutlin-3 could increase efficacy of PCI treatment in tumours where p53 is non-
functional due to MDM2 amplification.  
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1 Introduction  
 
1.1 Background 
The p53 gene is regarded as one of the most important genes in the development of human 
cancer [4]. Since its discovery more than 30 years ago, the tumour suppressor p53 has been 
subject of intense study yielding more than 60,000 PubMed-listed publications so far [5]. In 
1994, Hollstein and colleagues revealed that approximately 50% of all human malignancies 
have mutations in the TP53 gene, making it one of the most frequently mutated genes in 
human cancer [6].  The tumour suppressor p53 is often called ‘Guardian of the Genome’ due 
to its role in preventing cells with irreparable DNA damage to proceed in the cell cycle. 
Several different types of DNA damage activate p53, resulting in a rapid increase in the p53 
level in the cell and activation of p53 as a transcription factor [7]. This leads to a series of 
downstream events including cell cycle regulation and regulation of apoptosis, ultimately 
ensuring cellular and genetic stability [7]. 
 In addition to mutations in the TP53 gene, p53 can be inactivated by other aberrations 
in the signalling pathway. One such aberration is amplification of the Mdm2 gene or 
overexpression of the MDM2 protein. p53 and MDM2 form an autoregulatory feedback loop 
in which p53 positively regulates MDM2 levels and MDM2 negatively regulates p53 levels 
and activity [8]. In cells expressing wild-type p53 and normal levels of MDM2, various stress 
signals will lead to decrease in MDM2 protein levels and/or decrease in its interaction with 
p53, leading to p53 stabilization [9, 10]. In cells overexpressing MDM2, several studies have 
showed that p53 activity is attenuated, increasing the susceptibility for tumour formation [3]. 
A screening of more than 3000 tumours from 28 tumour types showed that of the tumours 
with mutation in either p53 or MDM2, only 4% showed mutations in both genes [3]. 
Therefore, antagonizing MDM2 to restore p53 function is a promising approach in cancer 
therapy. Different methods have been exploited to release p53 from MDM2 control including 
blocking MDM2 expression, inhibiting MDM2 ubiquitin ligase activity and inhibiting the 
MDM2-p53 binding [11]. Several classes of low molecular weight inhibitors of the p53-
MDM2 interaction have been reported to disrupt the binding of the two proteins [12]. In 
2004, Vassilev and colleagues at Roche Research Centre (Nutley, NJ, USA) discovered a 
series of cis-imidazoline analogues that can displace p53 from its complex with MDM2 [13]. 
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The compounds were given the name Nutlins, and have shown the ability to activate the p53 
pathway in vitro and in vivo in tumours expressing wild-type p53 [12].  
 
1.2 The cell cycle 
When DNA is damaged, for instance after irradiation or exposure to certain chemicals, it is 
crucial that this is repaired before the cells duplicate or segregate the chromosomes. 
Eukaryotic cells have evolved a complex network of regulatory proteins known as the cell 
cycle control system. This system monitors progression through the cell cycle and delays 
later events until earlier events have been completed. Preparations for the segregation of 
replicated chromosomes, for example, is inhibited until DNA replication is completed [14]. 
In this way, the cell will not proceed in the cell cycle with chromosomes that is either 
incompletely replicated or damaged, which can lead to development of cancer.  
 The cell cycles basic function is to duplicate the DNA in the chromosomes accurately 
and then segregate the copies precisely into two genetically identical daughter cells. This 
process is carried out in the two main phases of the cell cycle named S phase and M phase. In 
S phase the DNA duplication occurs with subsequent chromosome segregation and division 
in M phase. In addition to this there are two gap phases – G1 phase between M phase and S 
phase and G2 phase between S phase and M phase. These two gap phases allow time for 
growth and provide the cell with time to monitor the internal and external environment to 
ensure that everything is complete and that the conditions are suitable for the cell to enter the 
next phase [15].  
 At the end of each G-phase in the cell cycle, there is a checkpoint restricting the 
progression to the next phase. A family of protein kinases known as cyclin-dependent kinases 
(Cdks) govern these checkpoints, and the activity of these kinases fluctuates throughout the 
cell cycle. Their activity leads to cyclical changes in the phosphorylation of intracellular 
proteins that initiate or regulate the events in the cell cycle. The G1/S-cyclins, for example, 
binds Cdk at the end of G1 and commit the cell to DNA replication [16]. When the cell is 
exposed to radiation, chemicals or other potential harm, the cell-cycle control system detects 
the DNA damage and arrests the cell cycle at DNA checkpoints. Subsequently, DNA repair is 
induced, and upon completion the cell will continue in the cell cycle. In the event of 
irreparable damage, apoptosis is induced to ensure that a cell with DNA damage does not 
continue to replication or undergo mitosis [17]. The signals governing cell fate is largely 
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unclear, but the cell cycle checkpoint and signalling pathways inhibiting entry to S phase is 
known to be intimately associated with the tumour suppressor p53 [17, 18]. 
 
  
Figure 1.1: Illustration of the cell cycle in eukaryotic cells. At the checkpoints the status of the cell is controlled 
to make sure that the cell can continue to the next phase. If the cell at the G1/S checkpoint is not ready to 
continue to S-phase, the cell can go through a resting period (G0) until it is ready to divide. Adapted from 
Moodle.org [19] 
 
1.3 p53 
The biological role of p53 is as pointed out above to ensure genetic stability, and p53 is often 
referred to as the cell’s gatekeeper because if its role in the G1/S checkpoint. Upon DNA 
damage, p53 can stimulate the repair processes and protective mechanisms, or if necessary, 
the cessation of cell division and the induction of controlled cell death [17].  
In proliferating cells, the p53 protein is kept at a low level, predominantly through 
MDM2-mediated ubiquitination and degradation [20]. p53 is a potent anti-proliferative and 
pro-apoptotic protein, and high levels can therefore harm normal cells [11]. Normally, p53 
has a relatively short half-life of about 6-20 minutes, but when the degradation of the protein 
is inhibited following various forms of cellular stress, the half-life of p53 is lengthened to 
hours resulting in a 3-10-fold increase in p53-concentration in the cell [7, 21, 22]. Following 
p53 accumulation, the transcription of the gene encoding the cyclin-dependent kinase 
inhibitor (CKI) p21
Waf1
 is stimulated [14]. p21 is capable of silencing the Cdks which are 
essential for S phase entry, and thereby activating the G1/S checkpoint [18]. The checkpoint 
arrest following DNA damage has two potential impacts. It allows extra time for repair to 
take place before cell cycle progression, and it can permanently prevent proliferation in 
severely damaged cells [23]. Upon irreparable DNA damage, p53 can induce apoptosis 
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primarily through two distinct apoptotic signalling pathways. The extrinsic pathway involves 
engagement of particular ‘death’ receptors, leading to a cascade of activation of caspases, 
which in turn induce apoptosis [24]. The intrinsic pathway is associated with mitochondrial 
depolarization and release of cytochrome c from the mitochondrial intermembrane space into 
the cytoplasm leading to caspase activation. The intrinsic apoptotic pathway is dominated by 
the Bcl-2 family proteins including the pro-apoptotic protein Bax, which in response to stress 
activation forms a homodimer and releases cytochrome c from the mitochondria leading to 
caspase activation [24]. What determines if p53 induces cell cycle arrest or apoptosis upon 
DNA damage is only partially understood, and is subject of intense study. 
 
1.3.1 Non-functional p53 
In the early years of p53 research, the protein was mistakenly classified as an oncogene 
because high levels of p53 was detected in a number of tumour-derived cell-lines [5]. This 
perception was later challenged when it was revealed that the initially discovered p53 in fact 
was a mutant form of the protein. In sharp contrast to these mutant forms, wild-type p53 
turned out to be capable of supressing the malignant growth of transformed cells [25]. 
Following this discovery, p53 have been subject to extensive research with the objective to 
reveal what makes p53 lose its tumour suppressor properties, and what can be done to 
circumvent this loss of function. 
 The function of the TP53 gene is usually altered through mutations, loss of 
hetrozygosity (LOH) or in a few cases through DNA methylation [26]. In over 50% of 
tumours, TP53 is inactivated due to loss of function mutations and around 95% of them are 
found within the genomic region encoding the sequence-specific DNA-binding domain of 
TP53. These mutations disrupt the proper confirmation if those sequences, making mutant 
forms of TP53 lose the sequence-specific transactivation ability [26]. Thus, loss in p53 
activity alters the ability for DNA repair and may contribute to the development of cancer. 
 In some tumours with wild-type p53, other aberrations in the pathway such as the 
amplification of the Mdm2 gene or overexpression of the MDM2 protein can block p53 
function and promote growth of the tumour. Mutations in p53 and amplification of MDM2 
have shown to be largely independent of each other, and might therefore present a different 
approach in the search for more effective treatment of tumours with wild-type p53 [3].  
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Figure 1.2: Schematic illustration of the activation of the p53 pathway following DNA damage. Adapted from 
Matsumura et al. 2002 [27] 
 
1.4 Murine double minute 2 (MDM2)  
As mentioned previously, the level of p53 is kept low by MDM2-mediated regulation and 
physical and functional interaction between the two proteins [9]. MDM2 functions mainly, if 
not exclusively as an E3 ligase, targeting p53 for ubiquitylation and thereby controlling the 
protein level by proteasome-dependent degradation. In addition to degrading p53, MDM2 can 
antagonize p53 by concealing its transactivation domain. This is done by binding to an N-
terminal region of p53, thereby blocking its ability to associate with the transcriptional 
machinery [9].  
In a normal unstressed cell, any increase in the p53 level will subsequently activate 
MDM2 that in turn targets p53 for degradation. In response to stress, a decrease in MDM2 
protein levels and/or its activity and the interaction between MDM2 and p53 leads to p53 
stabilisation and subsequently activation of the p53 pathway [9]. This reduction of MDM2 in 
response to stress is crucial for p53 to exert its tumour suppressor activity.  
Around 50% of all tumours have non-functional p53 due to mutations, but the 
remaining 50% express wild-type p53 and are therefore capable of activating the p53 
pathway. However, aberrations in p53 regulation and/or defective signalling in the p53 
pathway is a frequent cause for inadequate tumour suppression [2]. One such aberration 
includes the murine double minute-2 gene product, MDM2. The MDM2 gene is found to be 
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abnormally upregulated in many human tumours including 13% of human esophageal 
carcinomas, 16% of osteogenic sarcomas and 20% of soft tissue sarcomas [2]. Amplification 
of MDM2 promotes cell growth, accelerates tumourigenesis and correlates with tumour 
incidence and clinical prognosis.  Since p53 mutations and MDM2 amplification tend to be 
mutually exclusive events, reactivating p53 through antagonising MDM2 has been proposed 
as a new approach in treatment of tumour retaining wild-type p53 [2]. 
 
1.5 Inhibiting the p53-MDM2 interaction 
Historically, it has been difficult to develop inhibitors of protein-protein interactions due to 
the large binding interface of the protein partners [28]. Protein interfaces are often large, flat 
and featureless, and frequently contain buried surfaces [2]. However, studies on the crystal 
structure of MDM2 revealed that the protein possesses a relatively deep hydrophobic cleft for 
p53 binding, with three amino acid residues contributing to a large part of the interaction and 
binding energy [2, 13]. To identify compounds that could inhibit the p53-MDM2 interaction, 
Vassilev et al. screened a diverse library of synthetic chemicals, identifying several 
promising compounds and optimised them for potency and selectivity [13]. One class of 
compounds that came out of this process was a series of cis-imidazoline analogues that was 
named Nutlins. These compounds displaced recombinant p53 protein from its complex with 
MDM2 with a mean inhibitory concentration (IC50) values in the 100 to 300 nM range [13]. 
Three Nutlins, Nutlin-1, Nutlin-2 and Nutlin-3 all disrupt the p53-MDM2 interaction, but 
Nutlin-3 is the compound most extensively evaluated for its therapeutic potential and 
mechanism of action [28]. The compounds were made as a racemic mixture from which the 
enantiomers could be separated. Only one of the enantiomers, called enantiomer-a, possessed 
potent binding activity and it was 150 times more active than the other enantiomer, 
enantiomer-b [13]. The active enantiomer of Nutlin-3 was purified, and is now known as 
Nutlin-3a [12]. 
 
1.5.1 Nutlin-3 
After its discovery almost 10 years ago, Nutlin-3 has been subject of extensive research. It 
has proven to be a potent and selective inhibitor of the p53-MDM2 interaction with excellent 
cell permeability. It induces accumulation and activation of p53 in cancer and normal cells 
without inducing DNA damage, thus being a non-genotoxic agent for the activation of p53 
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[28]. Proliferating cancer cells were effectively blocked in G1 and G2 phases, and underwent 
apoptosis when exposed to concentrations of Nutlin in the micromolar range [11].  
 Nutlin-3 has been studied in a vide variety of cell lines with different p53 and MDM2 
status. Studies including cytotoxic drugs in combination with Nutlin-3 have shown improved 
response to chemotherapy in cell lines retaining wild-type p53 [1, 29-32]. Several studies 
investigating the differences in response to Nutlin-3 in p53
Wt
 and p53
Mut
 cell lines has shown 
that Nutlin-3 induces cell cycle arrest and apoptosis in cell lines with p53
Wt
 and not in p53
Mut
 
[33-35].  
 While the efficiency of Nutlin-3 treatment of tumours with MDM2
Ampl
 and p53
Wt
 is 
confirmed in numerous studies, the response in cancer cells with normal levels of MDM2 is 
still unclear [1]. The apoptotic response of Nutlin-3 in these cell lines can vary dramatically, 
and future studies are necessary to investigate the utility of Nutlin-3 in cancer therapy. What 
tumour types that are particularly sensitive to inhibitors of the p53-MDM2 interaction, if 
treatments with these agents can lead to mutations in p53 or other defects in the p53 pathway 
and if the inhibitors can be used as monotherapy or in combination regimens in treatment of 
cancers with mutated p53, are amongst the other issues that needs to be addressed [28].  
 
 
1.6 Photodynamic therapy (PDT) 
1.6.1 Background 
The use of light as a therapeutic agent can be traced back thousands of years. It was used in 
ancient Egypt, India and China in the treatment of skin diseases, such as psoriasis, vitiligo 
and cancer, as well as rickets and even psychosis. However, it is only relatively recently that 
light has been used to any significant degree in medicine [36]. Throughout the 20
th
 century, 
many great discoveries were made in the field of photodynamic therapy (PDT). In 1901, the 
Danish physician Niels Finsen described the successful treatment of small pox using red 
light. Later, he used ultraviolet light to treat cutaneous tuberculosis. Finsen was awarded the 
Nobel Price in 1903 for his work in phototherapy [36]. In the 1960s, Richard Lipson and 
colleagues initiated the modern era of PDT at the Mayo Clinic. Through experiments they 
demonstrated that a compound called ‘haematoporphyrin derivative’ (HDP) was a 
photosensitizing agent, and thus had the capability to capture radiant energy and shuttle it 
into a biological system [37].  
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The application of PDT in cancer therapy took a long time to develop. In 1972, 
Diamond et al. published results indicating the possible use of haematoporphyrin as a 
selective photosensitizing agent to destroy tumour cells by exposure to visible light [38]. A 
significant breakthrough came in 1975 when Dougherty and colleagues reported that 
exposure of rat and mouse tumours to red light after injection of haematoporphyrin resulted 
in a substantial number of long-term cures [39]. In the last part of the 20
th
 century, the field of 
photodynamic therapy expanded substantially, including human trials, many new 
photosensitizing agents and new clinical applications. 
 
1.6.2 Principle 
Photodynamic therapy consists of 3 components: a photosensitizer (PS), light and oxygen. 
Individually, none of these components are toxic, but when a photosensitizer is irradiated in 
the presence of oxygen, a highly reactive product named singlet oxygen (
1
O2) is generated 
[40]. Following the absorption of light, the sensitizer is excited from its ground state, p
0
, to 
excited singlet stated, 
1
p*. From here it can return to the ground state by emitting a 
fluorescent photon (fluorescence) or to triplet excited state, 
3
p*, through intersystem crossing 
(ISC). From the triplet excited state, the sensitizer can return to the ground state by emitting a 
phosphorescent photon (phosphorescence), by internal conversion (IC) or by transferring 
energy to another molecule [41]. The latter can occur through two different reactions. It can 
transfer electrons (dominating) or hydrogen atoms directly to O2 or to a substrate to form 
radicals that later can interact with oxygen to produce oxygenated products (type I reaction). 
The second option is energy transfer from the excited triplet directly to ground-state 
molecular oxygen (
3
O2) to form excited O2, so called singlet oxygen (
1
O2) (type II reaction) 
[42]. Both type I and type II reactions may occur during treatment. Although type II reactions 
are reported to dominate during PDT [41], the ratio between the two reactions depend on the 
type of sensitizer used, the concentrations of substrate and oxygen and the binding affinity of 
the sensitizer for the substrate [42].  
The half-life of singlet oxygen in biological systems has been reported to be less than 
0,04 μs with a radius of action of less than 0,02 μm [43]. Consequently, only cells that are in 
close proximity to the accumulated photosensitizer, and thus the ROS generation, are directly 
affected by PDT [42]. The anti-tumour effects of PDT derive from 3 inter-related 
mechanisms. Direct cytotoxic effects on tumour cells are achieved by PDT generated ROS. 
The effectiveness of direct tumour-cell killing is dependent on the distribution of the 
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photosensitizer within the tumour and the availability of oxygen within the targeted tissue. 
Therefore, complete tumour eradication is not always possible with this mechanism alone. 
The second effect of PDT is damage to the tumour vasculature. PDT causes microvascular 
collapse, thus cutting off the tumours supply of nutrients and oxygen and thereby inducing 
cell death [42]. The last important anti-tumour effect of PDT is the induction of an 
inflammatory reaction which in turn can lead to the development of systemic immunity [40]. 
Reports indicate that, while the direct cytotoxic effects of PDT can destroy the bulk of the 
tumour, the immune response is required to eliminate the surviving cells. The relative 
importance of these 3 mechanisms is yet to be defined, but it is clear that a combination is 
necessary to ensure long-term tumour control [42]. 
 
 
 
Figure 1.3: Photosensitisation processes illustrated by a modified Jablonski diagram. Upon light exposure the 
molecule is excited from a ground singlet state (S0) to an excited singlet state (S1). It may then undergo 
intersystem crossing to an excited triplet state (T1) and then either form radicals via a Type I reaction or transfer 
its energy to molecular oxygen (
3
O2) and form singlet oxygen (
1
O2). Adapted from Agostinis et al. 2011 [40].  
 
1.6.3 Photosensitizers 
The ideal photosensitizer should meet several criteria: It should be a single pure compound to 
allow quality control with low manufacturing costs. Because the penetration of light into 
tissue increases with its wavelength, it should have a high absorption peak in the red to deep 
red area. It should have no dark toxicity and relatively rapid clearance from normal tissue, 
thereby minimalizing phototoxic side effects [40]. Some of the most useful photosensitizers 
for in vivo PDT are porphyrins, chlorins and bacteriochlorins [41]. Most of them are planar-
aromatic molecules composed of four symmetrically arranged pyrrol units linked by methine 
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bridges. They all have a strong absorption band around 400 nm, but this is not clinically 
relevant due to the low tissue penetration of blue light [41].  
 The first photosensitizer to be used in the clinic was the mixture of phorpyrins called 
hematoporphyrin derivative (HPD), which later was released on the market in the purified 
form with the name Photofrin® [40]. Photofrin® is the most commonly used and studied 
photosensitizer, but due to some disadvantages, including long-lasting skin photosensitivity 
and a relatively weak absorption band at 630 nm, there is a need for better photosensitizers 
[40, 41]. In recent years, several new photosensitizers have been developed. Foscan® 
(temoporfin), Visudyne® (verteporfin), Levulan® (5-aminolevulinic acid) and the precursor 
Metvix® (methyl aminolevulinate) have all been approved for clinical use, and several 
promising photosensitizers are currently in clinical trials [44].  
 
1.7 Photochemical internalisation (PCI) 
1.7.1 Background 
Macromolecules hold great potential in cancer therapy due to their prospects of higher 
therapeutic specificity than for most smaller molecular chemotherapeutic agents [45]. 
Macromolecules that are unable to pass directly through the cellular membrane because of 
their high molecular weight are therefore taken up into the cells by means of endocytosis [46, 
47]. Endocytosis involves internalisation of extracellular substances through invagination of 
the cell membrane, resulting in an endocytic vesicle containing the substances [46].  These 
endocytic vesicles (endosomes) have several potential destinations, mainly the lysosomal 
compartment for degradation, or recycling back to the cell surface [48]. For the therapeutic 
macromolecules with intracellular targets to exert their activity, they need to be released from 
the endosomes and enter the cytosol before they are degraded by lysosomal enzymes [49].  
 
1.7.2 Principle 
Photochemical internalisation (PCI) is based on the same principles as photodynamic therapy 
(PDT), and share many of the same characteristics [46]. PCI is a novel technology for release 
of endocytosed macromolecules into the cytosol [50]. The technology is based on the use of 
photosensitizers that locate in endocytic vesicles, and that upon activation by light disrupts 
the endocytic vesicle, thereby facilitating the release of the macromolecules [46, 50]. When 
the photosensitizer is exposed to light, reactive oxygen species (ROS) form the same way as 
for PDT. The chemical reactions induced by ROS ruptures the membrane, and allow the 
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molecules to vacate the endosomes [46]. This photochemically induced release is shown to 
occur without inducing extensive cell death, and with maintenance of the biological activity 
of the released molecules [51]. As pointed out above, singlet oxygen 
1
O2 has a very short 
lifetime and a short range of action, and may therefore destroy the membranes while the 
contents of the vesicles remain functionally intact [49]. Therapeutic agents for photochemical 
delivery include proteins toxins, oligonucleotids, nanoparticles and chemotherapeutic agents 
[46].  
 
 
Figure 1.4: Schematic illustration of PCI. A: Drugs taken up through endocytosis are transported to endosomes 
where they are degraded before they have exerted their action. B: PCI is based on accumulation of 
photosensitizer (PS) in endosomes and lysosomes. Light exposure causes rupture of the endo/lysosomal 
membrane and releases the drug into the cytosol where it can exert its action. Adapted from Weyergang et al. 
2011 [52].  
 
1.7.3 Photosensitizers 
For clinical use, the photosensitizers for PCI treatment should meet the same criteria as for 
PDT, considering toxicity, pharmacokinetics and light absorbance. In addition, 
photosensitizers used in PCI should have certain properties. They should localize in the 
endocytic vesicles. Within these vesicles, they should preferably localize to the membranes in 
order to give maximum damage to the membrane and minimum destruction of the 
internalized molecules. The aggregation of the photosensitizer within the cell should also be 
kept low, because aggregates reduce the ability of the photosensitizer to transfer the energy of 
the excited state to molecular oxygen [51]. The most efficient photosensitizers used in PCI 
have an amphiphilic structure with a hydrophilic part inhibiting penetration through cellular 
 17 
membranes [46, 50]. The photosensitizer will intrude into the plasma membrane and enter the 
cells via endocytosis, ending up in the inner leaflet of the endocytic vesicles [46].  
 Over the last 20 years, several hundred new photosensitizers have been developed for 
use in PDT. The most promising or approved ones exert with a few exceptions amphiphilic 
properties, but their ability to penetrate cellular membranes makes them unsuitable for use in 
PCI [50]. Photosensitizers with two sulfonate-groups instead of carboxyl-groups cannot 
penetrate cellular membranes, and are therefore applicable for PCI. Sulfonate groups have 
low pKa values, prohibiting protonation even in the acidic lysosomes [50].  
 The preclinical evaluation of PCI have been performed with the endosomally 
localized photosensitizers aluminium phtalocyanine disulfonate (AlPcS2a), disulfonated 
tetraphenyl porphine (TPPS2a) and disulphonated tetraphenyl chlorin (TPCS2a). AlPcS2a 
contains a large number of isomers potentially with batch-to-batch variations that might lead 
to differences in biological effects upon exposure to light [50]. A new chemical entity was 
needed for clinical use, and on this basis TPCS2a was developed.  The synthesized TPCS2a 
contains 3 isomers with low inter-batch variations and appears to be the first photosensitizer 
with strong absorption of light in the “therapeutic window” (600-800 nm) for photodynamic 
therapy, optimal properties for PCI and suitability for clinical use [50]. 
 
              
 
Figure 1.5: The figure shows the chemical structure and absorption spectra of TPCS2a. Adapted from Berg et al. 
2011 [50].  
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2 Materials and methods 
 
2.1 Cell culture 
2.1.1 Cell lines 
In this study, three cell lines with different TP53 and MDM2 status were used: MES-SA 
(ATCC® CRL-1976™), SK-LMS1 (ATCC® HTB-88™) and SJSA-1 (ATCC® CRL-
2098™). MES-SA is TP53Wt and MDM2 status is unknown. SK-LMS1 is TP53Mut and 
MDM2
Wt
. SJSA-1 is TP53
Wt
 and MDM2
Ampl
.  
Osteosarcoma cell line SJSA-1 was kindly provided by Professor Ola Myklebost 
(Department of Tumor Biology, The Norwegian Radium Hospital, Oslo). Uterine sarcoma 
cell line MES-SA and leiomyosarcoma cell line SK-LMS1 were both purchased from LGC 
Standards AB (Teddington, Middelsex, UK).  
 
2.1.2 Culture medium 
MES-SA was cultured in McCoy’s 5a medium (Sigma-Aldrich, St. Louis, MO, USA) 
supplemented with L-glutamine, 10% fetal bovine serum (FBS) (PAA Laboratories, 
Pasching, Austria), 100 IU/ml penicillin (Sigma-Aldrich) and 100 µg/ml streptomycin 
(Sigma-Aldrich). SK-LMS1 was cultured in Dulbecco’s modiﬁed Eagle's medium (DMEM) 
(Lonza Group Ltd, Basel, Switzerland) supplemented with L-glutamine, 10% FBS, 100 
IU/ml penicillin and 100 µg/ml streptomycin. SJSA-1 was cultured in RPMI-1640 medium 
(Sigma-Aldrich) supplemented with L-glutamine, 100 IU/ml penicillin and 100 µg/ml 
streptomycin.  All cell lines were cultured as monolayers in Nunclon™ surface treated tissue 
culture flasks (NUNC A/S, Thermo Fisher Scientific, Roskilde, Denmark) in incubators at 
37°C and 5% v/v CO2. 
 
2.1.3 Splitting of cells 
For optimal cell growth, it is important to make sure that the cells have enough nutrients and 
that the cells do not grow to confluence. This is done by checking the flasks in the 
microscope regularly. When the cells are approximately 80 % confluent (80 % of the flask’s 
surface are covered by a cell monolayer), the cells should be split into new flasks. Up until 
this point the cells are in the log-phase of growth, while in a more confluent flask, the cells 
may stop growing or die.  
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Procedure 
 Aspirate off the medium and rinse the cell layer with 2 ml Dulbecco’s Phosphate 
Buffered Saline without Ca & Mg (PBS) (PAA Laboratories). The washing removes 
any remnants of trypsin-deactivating enzymes from the serum.  
 Aspirate off the PBS, add 1 ml of 0,025%-0,5% trypsin/0,53 mM EDTA solution 
(Sigma-Aldrich), and incubate at 37ºC for a few minutes. Trypsin is a protease and 
will cleave the proteins attaching the cells to the surface of the flask.  
 After incubation, give the flask a few gentle taps, and then study the flasks in the 
microscope to ensure that the cells are detached.  
 Add 9 ml of pre-heated medium, and rinse the flask well by using the pipette 
 Transfer the desired amount of cell suspension to a new flask and add pre-heated 
medium, e.g. ≈20 ml in 75 cm2 flask and ≈40 ml in 175 cm2 flask. 
 
2.1.4 Counting of cells 
To determine cell concentration prior to an experiment, cells were counted manually using a 
KOVA® Glastic Slide disposable plastic hemocytometer (Hycor Biomedical, Indianapolis, 
IN, USA).  
 
Procedure 
 Trypsinate the cell monolayer in one or more flasks and add pre-heated medium.  
 Transfer 13 μl cell suspension to the hemocytometer chamber (if the cell suspension 
is dense, dilute the suspension to ease the counting) 
 Count 3 squares in diagonal. Divide the number by three and then multiply by 10 000 
to find the number of cells per ml 
 
2.1.5 Optimisation of cell plating 
Before starting the experiments, it was important to determine how many cells should be 
seeded per well of each cell line. This is done to avoid that the cells grow to confluence, 
which in turn can impair the growth of the cells and the reproducibility of the experiment. 
The procedure was designed to mimic a PCI experiment to give a realistic picture of how 
many cells we have in the control wells after five days. 
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Procedure 
 In 96-well plates, 2000 – 20 000 cells per well with intervals of 2000 cells were 
seeded on day 1.  
 On day 2, fresh medium was added. Following 18 hours incubation, the cells were 
washed twice with PBS and fresh medium was added.  
 On day 5, viability was measured using the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl 
tetrazolium bromide (MTT) assay.  
 
2.1.6 Growth curves  
Growth curves were established for each of the 3 cell lines to determine the doubling time. 
This is useful in the planning of experiments to estimate how many cells should be seeded to 
obtain a certain number of cells.  
 
Procedure 
 On day 1, 150 000 cells were seeded in BD Falcon™ 3001 culture dishes (BD 
Biosciences, Franklin Lake, NJ, USA).  
 After 24, 48, 72 and 96 hours, medium was aspirated, the dish washed once with PBS 
and 300 µl of trypsin was added.  
 After a few minutes of incubation at 37°C and 5% v/v CO2, 700 µl of medium was 
added and respectively 1, 0,5, 0,250, and 0,125 ml of the cell suspension was 
transferred to a small container and added coulter counter buffer to a total of 10 ml 
(Beckman Coulter Inc., Brea, CA, USA).  
 The cell suspension was mixed before the cell number was determined using a Z2™ 
Coulter Counter® Cell and Particle Counter (Beckman Coulter Inc.). 
 
2.1.7 Bleomycin 
The cell lines’ sensitivity to bleomycin was determined using the clonogenic assay (see 2.3.2)  
 
Procedure 
 On day 1, 400 cells per well of MES-SA, 600 cells per well of SJSA-1 and 800 cells 
per well of SK-LMS1 were seeded in 6-well plates and incubated overnight at 37°C 
and 5% v/v CO2 to allow the cells to adhere.  
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 On day 2, medium containing none, 0,05, 0,1, 0,5, 1 and 5 IU/ml Bleomycin were 
added to the wells.  
 Following 4-hour incubation, Bleomycin was removed and fresh medium was added.  
 The cells were incubated for 7-10 days until colonies of >50 cells formed. The 
colonies where then dyed and counted manually.  
 
2.1.8 Nutlin-3 
For the SJSA-1 cell line, the growth inhibition curves of Nutlin-3 determined by Ohnstad et 
al. [1] were used. For MES-SA and SK-LMS1, the growth inhibition by Nutlin-3 was 
determined using the clonogenic assay (see 2.3.2). 
 
Procedure 
 On day 1, 400 cells of MES-SA and 600 cells of SJSA-1 were seeded in 6-well plates 
and incubated at 37°C and 5% v/v CO2 overnight to allow the cells to adhere.  
 On day 2, medium containing none, 0,1, 0,5, 1, 2,5 and 5 µM Nutlin-3 was added.  
 On day 6, the cells were washed twice with PBS, and fresh medium was added.  
 The cells were incubated for 7-10 days. The colonies where then stained and colonies 
consisting of >50 cells were counted manually (see 3.2.3). 
 
2.2 PDT and PCI procedures 
2.2.1 Light source and photosensitizer 
PDT and PCI experiments were carried out using the LumiSource® light source (PCI Biotech 
AS, Oslo, Norway). The lamp is designed to provide homogenous irradiance over a defined 
illumination area of 45 x 17 cm. The lamp consists of four 18W Osram L 18/67 standard light 
tubes [53] emitting blue light with a peak wavelength of approximately 435 nm (figure 2.1).  
 The photosensitizer used in this study is TPCS2a (Amfinex®, PCI Biotech AS). 
TPCS2a is a disulfonated tetraphenyl chlorine developed by di-imide reduction of 
disulfonated tetraphenyl porphine (TPPS2a). The synthesized TPCS2a contains 3 isomers and 
absorbs light at 652 nm [50]. The amphiphilic nature of the molecule allows it to be 
incorporated into the cell membrane, while a hydrophilic area ensures that the sensitizer does 
not penetrate through the membrane. TPCS2a localizes in endocytic vesicles, which is crucial 
for its use in photochemical internalization. 
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Figure 2.1: Emission spectrum from LumiSource® (PCI Biotech AS) [53] 
 
2.2.2 PDT and PCI 
PDT and PCI experiments were carried out in Nunc 96 MicroWell™ or 6-well plates (NUNC 
A/S, Thermo Fisher Scientific) or Nunclon™ cell culture flasks, 25cm2 (NUNC A/S, Thermo 
Fisher Scientific) depending on the experiment. For western blotting, 6-well plates were used 
and for flow cytometry, 25 cm
2
 flasks were used because of the need for a high number of 
cells for further analysis. Clonigenic assay used in all experiments with Bleomycin (Baxter 
International Inc, Deerfield, IL, USA) for assessing cytotoxicity was carried out in 6-well 
plates in order to ease the counting of colonies. The MTT assay was used to assess viability 
in experiments including Saporin (Sigma-Aldrich) and was carried out in 96-well plates.  
 
PDT procedure 
 For all experiments, the cells were seeded in the appropriate type of plates and left for 
~24 hours to allow the cells to adhere.  
 On day 2, the cells were incubated in medium containing 0,2 µg/ml TPCS2a for 18 
hours 
 On day 3, they were washed twice with PBS. Fresh medium was added, and the cells 
were chased for 4 hours to allow the photosensitizer to be internalized and cleared 
from the cell membrane.  
 After the chase, the cells were illuminated using the LumiSource® lamp. 
 
For PCI treatment, the protocol was identical to that for the PDT procedure with a few 
additional steps. For all experiments with Bleomycin, the drug was added after the removal 
of the photosensitizer, and was washed away after the 4-hour chase before illumination. In 
experiments with Saporin, the toxin was added with the photosensitizer and incubated for 18 
hours before both substances were washed away.  
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2.3 Viability assays 
2.3.1 MTT-assay 
The MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay can be used 
to measure the viability of cells after a treatment. Since for most cell populations the total 
mitochondrial activity is related to the number of viable cells, this assay is broadly used to 
measure in vitro cytotoxic effects of drugs [54]. In viable cells, the yellow-colored 
tetrazolium salt MTT is converted into blue-colored formazan crystals by the mitochondrial 
enzyme succinate-dehydrogenase, which can be solubilised in different solutions such as 
methanol, ethanol, and DMSO [55]. Therefore, any increase or decrease in mitochondrial 
activity can be detected by measuring formazan concentration reflected in optical density 
(OD). The MTT-assay is an easy, sensitive and quick way of measuring acute cytotoxic 
effects of compounds [54]. 
 
Procedure 
 Prepare a 0,25 mg/ml MTT solution by diluting a 5 mg/ml stock solution in suitable 
medium  
 Aspirate off the medium from the wells. Add 100 µl MTT solution per well in 96-well 
plates, 1 ml in 6-well plates and 1 ml in BD Falcon™ 3001-dishes.  
 On each plate, add MTT solution to one row of empty wells. This will serve as the 
blank control 
 Incubate the plates at 37°C for ≈3-5 hours until visible formazan crystals are formed 
 Aspirate off the MTT solution. Add 100 µl DMSO (Sigma-Aldrich) per well in 96-
well plates, 1 ml per well in 6-well plates and in BD Falcon™ 3001-dishes. 
 Gently shake for ≈5-10 minutes until the formazan crystals have dissolved 
 For the 6-well plates and the 3001 dishes; transfer 100 µl to wells in a 96-well plate 
 Measure the optical density at 570 nm using a Powerwave XS2 microplate 
spectrophotometer (BioTek, Winooski, VT, USA) and analyse the data using the 
Gen5™ Data Analysis Software (BioTek).  
 
2.3.2 Clonogenic cell survival assay  
A disadvantage of the MTT-assay is that the method can sometimes overestimate or 
underestimate cytotoxicity of a compound by not taking into account reversible damage or re-
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growth of cells resistant to the drug/cytotoxic agent. It can also underestimate cellular 
damage and cell death because it works best for detecting the later stages of apoptosis [56]. 
For certain compounds, it might therefore be advisable to include clonogenic cell survival 
assays when determining in vitro cytotoxicity.  
The clonogenic cell survival assay is a much-used method to measure the long-term 
cytostatic effects of a drug/cytotoxic agent. It allows us to determine the ability of a single 
cell to form a clone, proliferate and produce a viable colony [56]. In this study, clonogenic 
assay was used to measure cell survival in all experiments involving bleomycin, and a 
modified version of the protocol by Franken et al. [57] was utilised.  
 
Procedure 
 400 cells per well of MES-SA, 600 cells per well of SJSA-1 and 800 cells per well for 
SK-LMS1 were seeded in 6-well plates, and treated according to the PDT and PCI 
protocols 
 After 8-10 days depending on the cell line, visible colonies of at least 50 cells [57] 
were formed 
 The medium was aspirated off and the colonies were washed once with 0,9% saline 
(Fresenius Kabi, Halden, Norway).  
 The cells were fixed with ≈1 ml absolute ethanol (Kemetyl Norge AS, Vestby, 
Norway) for 10-30 minutes  
 The ethanol was aspirated off. The colonies were stained with methylene blue for at 
least 5 minutes 
 The methylene blue was aspirated off and the plates gently rinsed in tap water  
 The plates were studied under the microscope to determine which colonies consisted 
of >50 cells. These colonies were counted manually 
 
2.4 Analysis of protein expression by SDS-
PAGE/Western blotting 
 
In this study, analysis of protein expression by SDS-PAGE and western blotting were done to 
investigate the impact different treatments had on the expression of MDM2, p53, p21 and 
Bax.  
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2.4.1 Sample preparation 
The experiments were carried out in 6-well plates to ensure enough proteins for the protein 
analysis. To avoid changes in growth that might affect the protein expression, it is important 
that the wells do not grow to confluence. 200 000 cells of SJSA-1 and 350 000 cells of MES-
SA were seeded in each well. These numbers were determined based on the preliminary 
experiments on plating density. 
 
Procedure 
 At the desired time post treatment, put the dishes or 6-well plates on ice to stop any 
further cellular processes 
 Aspirate off the medium. Ad 1 ml ice cold PBS without Mg2+ and Ca
2+
 and tilt the 
dish gently 
 Aspirate off the PBS. Add 70 µl of lysis buffer (appendix A). Tilt the dish to cover 
the bottom 
 Use a cell scraper to collect the lysate. Transfer the lysate to Eppendorf tubes 
 Sonicate the tubes (4710 Series Ultrasonic Homogenizer, Cole-Parmer Instrument 
Co., Chicago, IL, USA). Vortex and spin down 
 Allocate the lysate to Eppendorf tubes. Freeze at -80°C 
 
2.4.2 Measurement of relative protein content 
The relative protein content in the samples is measured to make the protein loading on the gel 
as even as possible.  
 
Procedure 
 Dilute 20 µl sample buffer (appendix A) 1:50 in dH2O and 20 µl cell lysate 1:25 in 
dH2O 
 Wash a cuvette (black quartz, pathlength 10 mm, “Z” dimension 15 mm) twice with 
the diluted sample buffer. Then calibrate the spectrophotometer (Ultrospec 2100 pro 
UV/Visible, GE Healthcare Life Sciences, Uppsala, Sweden) with 80 µl of the buffer 
 For each sample, wash the cuvette twice with 80 µl of the sample and then add 80 µl 
of the sample to the cuvette for measurements. Analyse each sample 3 times 
 Calculate the mean protein content of the 3 parallels 
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 Fifteen µl of the sample with the lowest protein content will be applied on the gel. 
The other samples will be added in volumes to ensure that similar protein contents are 
added to each well.  
 
2.4.3 Gel casting 
The polyacrylamide gel is cast in two layers, the upper stacking gel and the main separating 
gel. The stacking gel has a low percentage (usually 3% w/v) of acrylamide through which 
proteins of all sizes readily migrate in the electric field. The purpose of the stacking gel is to 
“stack” all the proteins into a concentrated layer before entering the separating gel [58]. The 
separating gel has an acrylamide content of 5% - 17,5% depending on the size of the proteins 
to be studied. A higher acrylamide concentration gives smaller pores in the gel that in turn 
retards the proteins more. In this study, proteins ranging in size from 21 kDa to 60 kDa were 
studied. A gel with 12% acrylamide was chosen because this is optimal for the size range 
14,4 – 65 kDa.  
 
Procedure 
 Wipe down the glass plates with 70% ethanol and set up the glass plate sandwich in 
the gel-casting stand. Make sure there are no leaks by wrapping the bottom half of the 
glass plate sandwich in Parafilm® M (Sigma-Aldrich) 
 Mix all the components for the separating gel (appendix A) and the stacking gel 
(appendix A) except for APS and TEMED 
 Add APS to the separating gel. Mix by inverting the tube a few times. Then add the 
TEMED and mix by inverting the tube a few times. The gel will now begin to 
polymerize 
 Pipette the separating gel mix into the gel casting mould until the solution fills around 
¾ of the mould 
 Allow the gel to polymerize for 30-45 minutes 
 Add APS to the stacking gel. Mix by inverting the tube a few times. Then add the 
TEMED and mix by inverting the tube a few times 
 Pipette the stacking gel mix into the gel casting mould until it is full. Insert the comb 
into the top of the mould 
 Allow the gel to polymerize for 20-30 minutes 
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 Use the gel immediately, or wrap it in Parafilm® M and aluminium foil and store it at 
4ºC for up to a week.   
 
2.4.4 SDS-PAGE 
SDS-PAGE relies on the migration of charged molecules in a gel matrix in response to an 
electrical field. This technique facilitates the separation and resolution of a mixture of 
proteins according to molecular weight [58]. In this study, SDS-PAGE was carried out under 
reducing conditions. This involves the linearization of proteins by the dissociation of inter- 
and intrachain disulfide bonds, which is achieved by heating the protein sample briefly at 
95ºC in the presence of the reducing agent dithiotreitol (DTT). The proteins are also coated 
with a negative charge in the presence of the anionic detergent SDS. They are then separated 
and resolved as discrete bands as they migrate in an electric field through the “sieving” action 
of the acrylamide gel matrix [58].  
 As a standard for protein size, a ladder consisting of a coloured component (Precision 
Plus Protein™ Kaleidoscope, Bio-Rad Laboratories, Hercules, CA, USA) and a protein 
component (Biotinylated Protein Ladder, Cell Signaling Technology, Danver, MA, USA) 
were applied on the gel alongside the samples. The coloured ladder allows us to see how the 
proteins migrate on the gel, and can be used as a visual control that the protein transfer from 
the gel to the membrane was successful. The protein ladder is visible on the developed 
western blot, and allows us to check the size of the proteins in our samples.     
 
Procedure 
 Prepare the ladder; 2 parts Kaleidoskop (Bio-Rad), 1 part Biotinylated ladder (Cell 
Signaling) and 2 parts sample buffer 
 Pierce a hole in the tubes with sample and ladder. Heat at 95°C for 5 minutes 
 Put the tubes on ice. Vortex and spin down 
 Apply 10 µl ladder and the appropriate amount of sample on the gel 
 Fill the chamber with running buffer (appendix A). Run the gel electrophoresis on ice 
at 200 V and 400 mA for ≈45 minutes  
 
2.4.5 Western Blotting  
After the proteins have been separated on the gel, they have to be transferred to a 
nitrocellulose or polyvinylidene difluoride (PVDF) membrane before they can be probed for 
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reactivity with different types of affinity reagents, such as antibodies [59]. This process is 
called western blotting, and usually takes place in a semidry buffer system using wetted filter 
papers sandwiched between planar electrodes. In this study, PVDF membranes (GE 
Healthcare Life Sciences) were used because of their high protein binding capacity, physical 
strength and chemical stability [60]. The membrane is extremely hydrophobic, and must 
therefore be pre-wetted in methanol prior to submersion in transfer buffer.  
 
Procedure 
 Soak a polyvinylidene difluoride (PVDF) membrane in methanol and then in the 
transfer buffer (appendix A) 
 Assemble the blotting cassette as follows: pad, filter paper, gel, membrane, filter 
paper, pad (figure 2.2).  
 Position the cassette in a blotting tank put on ice with a magnetic stirrer. Fill the tank 
with transfer buffer 
 Run the blotting at 100 V and 400 mA for 2 hours at 4°C 
 
   
Figure 2.2: Illustration of the electrophoretic protein transfer from the polyacrylamide gel to the PVDF 
membrane. The proteins migrate to the membrane following a current that is generated by applying a voltage 
across the electrodes. Figure adapted from Leinco Technologies, Inc. [61] 
 
2.4.6 Immunodetection 
After transfer, the excess protein binding sites on the membrane must be blocked to avoid 
non-specific binding of antibodies. This can be done with solutions of proteins such as bovine 
serum albumin, non-fat dry milk or casein [59]. Following blocking, probing with antibodies 
is done in two steps; first with the primary antibody and then with the secondary antibody. 
The primary antibody binds to antigens on the membrane, and the secondary antibody binds 
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to the Fe-region on the primary antibody [59]. For this study, the recommendations for 
protein solutions from the antibody manufacturers were followed (appendix B).  
 
Procedure 
 Wash the membrane 3 x 10 minutes with 12 ml 1x TTBS (appendix A) 
 Block the membrane with 15 ml 5% w/v non-fat dry milk (appendix A) for 1 hour at 
room temperature 
 Incubate the membrane with primary antibody diluted in 5 ml 5% w/v non-fat dry 
milk or 5% w/v BSA (appendix A) overnight at 4°C 
 Wash the membrane 3 x 10 minutes with 12 ml 1x TTBS 
 Incubate the membrane with secondary antibody diluted in 5 ml 5% w/v non-fat dry 
milk for 1 hour at room temperature. Use anti-rabbit antibody for primary antibodies 
of rabbit origin etc. Use anti-biotin for the ladder 
 
The secondary reagents are conjugated with an enzyme, usually horseradish peroxidase 
(HRP) or alkaline phosphatase (AP). HRP catalyses the oxidation of the luminol in the 
chemiluminescent substrate (LumiGLO®, KLP Inc., Gaithersburg, MD, USA), subsequently 
producing an excited state product that emits light [60]. The light is captured on an x-ray film 
(Amersham Hyperfilm ECL, GE Healthcare Life Sciences), and this film is then developed. 
The light emitted is proportionate with the amount of protein, so the blots can be quantified 
by comparing the bands in the different lanes. 
 
Procedure 
 Wash the membrane 3 x 10 minutes with 12 ml 1x TTBS 
 Incubate with 1ml LumiGlo A and LumiGlo B (1:1) for 5 minutes at room 
temperature 
 Fix the membrane between 2 transparent sheets in an exposure cassette. Gently 
smooth out any air pockets 
 Place an x-ray film on top of the membrane, close the cassette and leave it for the 
desired exposure time 
 Develop the film using the Agfa Curix 60 Film Processor (Agfa-Gevaert N.V., 
Mortsel, Belgium) 
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2.5 Flow cytometry   
2.5.1 Principle 
Flow cytometry is a technology in which a variety of measurements are made on cells, cell 
organelles, and other objects suspended in a liquid. Cells in suspension are made to flow one 
at a time through a sensing region of a flow chamber (flow cell) where measurements are 
made [62]. In the flow chamber, the cells are exposed to monochromatic light, usually from a 
laser, that upon hitting the cells scatter in all directions. Analysis of the scattered light 
provides information about the cell size and structure. The intensity of the forward-scattered 
light correlates with cell size. The intensity of the side-scattered light correlates with 
granularity, refractiveness and the presence of intracellular structures that can reflect the light 
[63]. Scattered light is collected via optics that directs the light to a series of filters and 
mirrors that isolate particular wavelength bands. The light signals are detected and digitalized 
for further analysis [64]. 
Flow cytometry measures optical and fluorescence characteristics of single cells. 
Physical properties, such as size and internal complexity can be used to distinguish certain 
cell populations. Fluorescently labelled antibodies can be used to identify a large number of 
cell surface and cytoplasmic antigens. Fluorescent dyes that incorporate into the DNA helical 
structure are used for measurement of cellular DNA content. The fluorescent signal is 
directly proportional to the amount of DNA in the nucleus, and can identify gross gains or 
losses in DNA [64]. 
 
 
Figure 2.3: Example of the schematic of a flow cytometer. A single cell suspension is hydrodynamically 
focused with sheath fluid to intersect an Argon-Ion laser. Signals are collected by a forward angle light scatter 
detector, a side scatter detector (1), and multiple fluorescence emission detectors (2-4). The signals are 
amplified and converted to digital form for analysis and display on a computer screen [10]. 
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2.5.2 Sample preparation 
The experiments were carried out in 25 cm
2
 flasks to ensure enough cells for further analysis. 
To avoid changes in growth that might affect the results, it is important that the flasks do not 
grow to confluence. In the flasks that were to receive PDT or PCI treatment, 500 000 cells 
were seeded. In the remaining flasks, 300 000 cells were seeded. The difference in plating 
density is due to the amount of cells that are lost during PDT and PCI treatment. The cells 
were treated according to the PDT and PCI protocol and harvested 2 and 20 hours post 
treatment.  
 
Procedure 
 Aspirate off the medium and wash once with 500 µl PBS. Transfer both medium and 
PBS to flow tubes 
 Add 500 µl trypsin and leave in the incubator for a few minutes. Check in the 
microscope that the cells are detached 
 Add 500 µl PBS and transfer to the flow tubes with the medium and the PBS 
 Centrifuge at 2000 rpm for 4 minutes 
 Aspirate off the supernatant and add 4 ml of PBS 
 Centrifuge at 2000 rpm for 4 minutes 
 Aspirate off the PBS and re-suspend in 500 µl ice cold methanol.   
 
2.5.3 Analysis 
In this study, flow cytometry was used for cell cycle analysis, study of DNA double strand 
breaks and to estimate the number of apoptotic cells after PDT and PCI treatment with or 
without added Nutlin-3. The fixed cells were first incubated with the TdT reaction solution. 
The components of this solution make up the TUNEL-assay, which is an assay that can 
identify cells undergoing apoptosis by labelling the ends of degrading DNA with the 
polymerase terminal deoxynucleotidyl transferase (TdT). When labelled nucleotides are 
incorporated by TdT, nuclei with degrading DNA can easily be detected by standard 
immunohistochemical or immunofluorescent techniques [65]. To detect DNA double strand 
breaks, the cells were incubated with γH2AX antibody (Millipore Corporation, Billerica, 
MA, USA). When DNA is damaged and DNA double strand breaks occur, the histone H2AX 
is phosphorylated and γ-H2AX foci are formed. These foci represent DNA double strand 
breaks in a 1:1 manner, and can therefore be used as a biomarker for such damage [66]. 
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Finally, the cells are stained with Hoechst 33258. Hoechst is a fluorescent dye that stains 
DNA. The basis for the cell cycle analysis is measurement of DNA content in the cell, 
because this varies throughout the cell cycle. To ensure uniformity of single cell suspensions 
and remove cell aggregates, the suspension is filtered into BD Falcon™ tubes (BD 
Biosciences) through a 35 μm nylon mesh (BD Biosciences). The samples were analysed by 
the staff at the flow cytometry core facility on a BD LSR II Flow Cytometer (BD 
Biosciences).  
 
Procedure 
 Wash once with ≈4 ml PBS (centrifuge at 2000 rpm for 4 minutes) 
 Add 35 µl TdT reaction solution (appendix A), incubate at 37°C for 30 minutes 
 Wash once with PBS  
 Add 50 µl 5% dry milk in PBS with 1/500 mouse α-γH2AX and 1/500 rabbit α-P-
Histone H3. Incubate at room temperature for 30 minutes 
 Wash twice with PBS 
 Add 50 µl 5% dry milk in PBS with 1/50 goat α-rabbit-PE, 1/50 rabbit α-mouse-FITC 
and 1/400 streptavidine-Cy5. Incubate at room temperature for 30 minutes 
 Wash once with PBS and add 300 µl 1,5 µg/ml Hoechst 33258. Incubate at room 
temperature for 30 minutes 
 Filter and transfer to appropriate tube before analysis 
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3 Results 
 
3.1 Growth curves and density curves 
For optimal results of many experiments, including viability assays, it is important that the 
cells do not grow to confluence. When the cells approach confluence, the growth rate 
decreases, and cells may start to die. Growth curves and density curves were therefore 
obtained for the three cell lines SK-LMS1, MES-SA and SJSA-1 to determine optimal 
plating density.  
 
3.1.1 Density curves 
The cells were seeded out at different cell densities in 96-well plates, and the optical density 
was measured 5 days post plating using the MTT assay as described in 2.3.1.  
The density curves for SK-LMS1 (figure 3.1A) and MES-SA (figure 3.1B) cells show 
linear growth up to approximately 12 000 cells seeded per well. When more than 12 000 cells 
were seeded in each well in a 96-well plate, the curve levelled off indicating non-exponential 
growth. For later experiments, SK-LMS1 and MES-SA cells were therefore seeded at a 
density of 4000 cells per well. The density curves for SJSA-1 (figure 3.1C) show linear 
growth up to approximately 10 000 cells seeded. To avoid confusion, 4000 cells per well in 
96-well plates were also seeded of SJSA-1 cells. This number is low enough to avoid the 
cells growing confluent, while ensuring enough cells for detection by the MTT assay.  
 
3.1.2 Growth curves 
For experiments involving western blotting or flow cytometry, it is crucial to isolate a high 
number of cells. It is therefore important to seed enough cells in the beginning of the 
experiment, but not so many that the cells grow to confluence. Growth curves (figure 3.1D) 
were obtained to study the doubling time of the different cell lines, to determine how many 
cells to seed for the experiments. Estimated doubling time (Td) for SK-LMS1 was 30 hours, 
27 hours for SJSA-1 and 20 hours for MES-SA.  
 
Doubling time (Td) was calculated using the following formula [67]: 
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Where t is the duration of the exponential growth phase, Nt is the number of cells after the 
exponential phase and N0 is the number of cells before the exponential phase.  
 
A      B 
 
C      D 
 
Figure 3.1: Density curves for SK-LMS1 (A), MES-SA (B) and SJSA-1 (C). The optical density at different 
plating densities was measured with the MTT assay. D: Growth curves for SK-LMS1, MES-SA and SJSA-1. 
The number of cells was counted 0, 24, 48, 72 and 96 hours post plating. All figures show a representative result 
from a single experiment. Error bars represent the empiric standard deviation (n=3).  
 
3.2 Bleomycin sensitivity 
Before initiating experiments with bleomycin, the three cell lines were tested using the 
clonogenic assay to determine their bleomycin sensitivity. Bleomycin is a slow acting 
chemotherapeutic agent, and requires many days to fully exert its therapeutic potential. Thus, 
the therapeutic effect of bleomycin is usually assessed by a clonogenic assay. In 6-well 
plates, 400 cells per well of MES-SA, 600 cells per well of SJSA-1 and 800 cells per well of 
SK-LMS1 were seeded and treated with 0 – 5 IU/ml Bleomycin for 4 hours. The cells were 
then incubated for 8-10 days until visible colonies were formed, the colonies were stained 
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and counted manually. The surviving fraction was calculated and LD50 was estimated. For 
MES-SA (figure 3.2B), LD50 was approximately 0,1 IU/ml bleomycin and for SK-LMS1 
(figure 3.2A) and SJSA-1 (figure 3.2C) LD50 was approximately 0,3 IU/ml.  
A      B 
 
C 
 
Figure 3.2: Bleomycin sensitivity of SK-LMS1 (A), MES-SA (B) and SJSA-1 (C). All figures show a 
representative result from a single experiment. Error bars represent the empiric standard deviation (n=3).  
 
3.3 PDT and PCI with TPCS2a  
3.3.1 PDT and PCI with TPCS2a and saporin  
The results of PDT and PCI treatment of SK-LMS1, MES-SA and SJSA-1 cells are shown in 
figure 3.3-3.5.  To study the effect of treatment with saporin the MTT assay was utilised, and 
4000 cells per well in 96-well plates were seeded. The cells receiving PDT were incubated 
with 0,2 μg/ml TPCS2a. The cells receiving PCI treatment were incubated with 0,2 μg/ml 
TPCS2a and 0,06 μg/ml, 0,3 μg/ml or 1,0 μg/ml saporin. Following the 18-hour incubation 
with TPCS2a with or without saporin, the cells were chased for 4 hours, treated with light 
doses ranging from 0 - 250 seconds (0 - 2,675 J/cm
2
) and examined by the MTT assay 48 
hours post light. There were great differences in the response to the treatment in the 3 cell 
lines. 
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The PCI effect was calculated using the following formula: 
 
 
MES-SA cells responded well to PDT (figure 3.4). To reduce the viability to 20%, a light 
dose of 110 seconds was necessary. SK-LMS1 (figure 3.3) and SJSA-1 (figure 3.5) cells were 
less sensitive to PDT, requiring a light dose of 240 and 175 seconds respectively to induce 
the same loss of viability. The cells response to PCI treatment was stronger. To induce an 
80% loss of viability when treated with PCI of 0,06 μg/ml saporin, SK-LMS1 cells required a 
light dose of 95 seconds (figure 3.3A), MES-SA cells 20 seconds (figure 3.4A) and SJSA-1 
cells 15 seconds of light exposure (figure 3.5A). The PCI effect was therefore 2,53 in SK-
LMS1 cells, 5,5 in MES-SA cells and 11,67 in SJSA-1 cells.  
A            B 
 
 
 
 
 
 
 
 
 
 
 
C 
 
 
 
 
 
 
 
 
 
Figure 3.3: PDT and PCI of SK-LMS1 cells with 0,06 μg/ml (A), 0,3 μg/ml (B) and 1,0 μg/ml (C) saporin and 
increasing light dose. All figures show a representative result from a single experiment. Error bars represent the 
empiric standard deviation (n=3).  
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A      B 
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Figure 3.4: PDT and PCI of MES-SA cells with 0,06 μg/ml (A), 0,3 μg/ml (B) and 1,0 μg/ml (C) saporin and 
increasing light dose. All figures show a representative result from a single experiment. Error bars represent the 
empiric standard deviation (n=3).  
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Figure 3.5: PDT and PCI of SJSA-1 cells with 0,06 μg/ml (A), 0,3 μg/ml (B) and 1,0 μg/ml (C) saporin and 
increasing light dose. All figures show a representative result from a single experiment. Error bars represent the 
empiric standard deviation (n=3).  
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3.3.2 PDT and PCI with TPCS2a and bleomycin  
The results of PDT and PCI treatment of SK-LMS1, MES-SA and SJSA-1 cells are shown in 
figure 3.6.  To study the effect of treatment with bleomycin the clonigenic assay was utilised. 
800 cells per well of SK-LMS1 and 600 cells per well of SJSA-1 were seeded in 6-well plates 
and 1000 cells of MES-SA per 25 cm
2
 flask were seeded. The cells receiving PDT were 
incubated with 0,2 μg/ml TPCS2a. The cells receiving PCI treatment were incubated with 0,2 
μg/ml TPCS2a for 18 hours and different doses of Bleomycin for 4 hours. MES-SA and 
SJSA-1 cells was treated with 0,1 IU/ml Bleomycin and SK-LMS1 cells with 0,3 IU/ml 
Bleomycin. The cells received light doses ranging from 0 – 150 seconds (0 - 1,605 J/cm2). 
After 10 days, the colonies were stained and counted manually. 
 
A      B 
 
C 
 
Figure 3.6: Clonogenic survival after PDT and PCI treatment of A: SK-LMS1 with 0,3 IU/ml bleomycin B: 
MES-SA with 0,1 IU/ml bleomycin C: SJSA-1 with 0,1 IU/ml bleomycin. All figures show a representative 
result from a single experiment. Error bars represent the empiric standard deviation (n=3).  
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SK-LMS1 (figure 3.6A) and MES-SA (figure 3.6B) cells had similar response to PDT 
requiring light doses of 145 and 150 seconds respectively to induce an 80% loss of viability. 
SJSA-1 cells (figure 3.6C) appear to be the most sensitive of the three cell lines to PDT with 
a light dose of 95 seconds required to reduce the viability to 20%. The viability of both MES-
SA and SJSA-1 cells was reduced to 20% when treated with PCI of 0,1 IU/ml bleomycin and 
a light dose of 70 seconds. SK-LMS1 cells appear to be less sensitive to PCI treatment than 
the two other cell lines, requiring a light dose of 90 seconds to induce an 80% loss of viability 
when treated with PCI of 0,3 IU/ml bleomycin.  
 When comparing the PCI effects on the three cell lines, it is important to bear in mind 
that SK-LMS1 cells were treated with 0,3 IU/ml bleomycin, while SJSA-1 and MES-SA cells 
were treated with 0,1 IU/ml bleomycin. The PCI effect of SK-LMS1 cells can therefore not 
be compared with the PCI effect of the other two cell lines. The PCI effect was 1,61 in SK-
LMS1 cells, 2,14 in MES-SA cells and 1,36 in SJSA-1 cells.  
 
3.3.3 PDT and PCI with TPCS2a and saporin ± Nutlin-3 
The effect Nutlin-3 had on the cell survival after PDT and PCI treatment with TPCS2a and 
saporin were studied using the MTT assay (figure 3.7). SJSA-1 cells were seeded out in 96-
well plates with a plating density of 4000 cells per well. The cells were incubated with 0,2 
μg/ml TPCS2a and 0,06 μg/ml, 0,03 μg/ml or 0,01 μg/ml saporin. Lower doses of saporin 
were used for this experiment because the previous experiment on SJSA-1 cells with saporin 
showed high toxicity of saporin in this cell line. Following an 18-hour incubation, the 
photosensitizer and saporin was washed away with PBS without Ca & Mg. Half the wells 
were added 500 nM Nutlin-3, which was not removed until immediately before MTT. After 4 
hours, the cells were treated with light doses ranging from 0 - 250 seconds (0 - 2,675 J/cm
2
) 
and examined by the MTT assay 48 hours post treatment.  
 This experiment showed very small differences in loss of viability between the PDT 
and PCI treated SJSA-1 cells that were incubated with 500 nM Nutlin-3, and those that were 
not. There seems to be bigger differences after PDT (figure 3.7A) than after PCI treatment 
(figure 3.7B-D), but the experiment needs to be repeated to confirm this. In the PCI treated 
cells there were no distinct differences in loss of viability between the saporin doses, but 
0,01-0,06 μg/ml saporin induced a substantial loss of viability so it might be wise to repeat 
the experiments with lower doses of saporin, to better see any potential differences. 
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A      B 
 
C      D 
 
Figure 3.7: PDT (A) and PCI treatment of SJSA-1 cells with 0,01 μg/ml (B), 0,03 μg/ml (C) and 0,06 μg/ml 
(D) saporin, with or without added 500 nM Nutlin-3. All figures show a representative result from a single 
experiment. Error bars represent the empiric standard deviation (n=3).  
 
A      B 
 
Figure 3.8: Clonogenic survival after PDT (A) and PCI (B) treatment with bleomycin of SJSA-1, with or 
without 500 nM Nutlin-3. All figures show a representative result from a single experiment. Error bars represent 
the empiric standard deviation (n=3).  
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3.3.4 PDT and PCI with TPCS2a and bleomycin ± Nutlin-3 
The effect Nutlin-3 has on the cell survival after PDT and PCI treatment with TPCS2a and 
bleomycin was studied using the clonogenic assay (figure 3.8). SJSA-1 cells were seeded in 
6-well plates with a plating density of 600-1200 cells per well. The cells to be treated with 
PDT and PCI were incubated with 0,2 μg/ml TPCS2a for 18 hours. The cells were then 
washed twice with PBS without Ca & Mg and 0,1 IU/ml Bleomycin were added to the wells 
to be treated with PCI or bleomycin only. Half of the wells were in addition treated with 500 
nM Nutlin-3. After 4 hours, the Bleomycin was removed and half the wells were continued to 
be treated with 500 nM Nutlin-3 until the colonies were counted. The cells to be treated with 
PDT and PCI were treated with light doses ranging from 0 – 150 seconds (0 - 1,605 J/cm2). 
After 10 days, the colonies were stained and counted manually.  
 Both for the PDT and PCI treated cells, there seem to be a greater loss in viability in 
the cells incubated with Nutlin-3. As in the experiment with Saporin, the difference appears 
to be greater in the PDT treated cells (figure 3.8A). This experiment has not been reproduced, 
so it needs to be repeated to confirm these results and to be able to quantify the differences.  
 
3.4 Analysis of protein expression 
To investigate the impact Nutlin-3 has on the p53 signalling, expression of p53, MDM2, p21 
and Bax was measured by SDS-PAGE, western blotting and immunodetection (figure 3.9-
3.12). In 6-well plates, 150 000 – 200 000 SJSA-1 cells per well were seeded and treated 
according to the PDT and PCI protocols. The cells to be treated with PDT and PCI were 
incubated with 0,2 μg/ml TPCS2a for 18 hours, before the photosensitizer was washed away 
with PBS without Ca & Mg. The PCI and BLM cohorts were then incubated with 0,1 IU/ml 
bleomycin for 4 hours before the PDT and PCI cohorts were illuminated for 160 seconds. 
During the chase period and until the cells were harvested, half the wells were treated with 
500 nM Nutlin-3. The cells were harvested 8, 24 and 48 hours post light. The protein 
expression was measured according to the SDS-PAGE, western blotting and 
immunodetection protocols (section 2.4).  
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Figure 3.9: Expression of p53 in SJSA-1 cells after PDT, PCI and BLM treatment in the absence or presence of 
Nutlin-3. The results were normalised with respect to total γ-tubulin, relative to untreated cells.  The figure 
shows the result from one experiment.  
 
3.4.1 p53 
The expression of p53 after PDT, PCI and bleomycin treatment was measured 8, 24 and 48 
hours post light (figure 3.9). The level of p53 in the cells treated with only Nutlin-3 (red 
column) is higher than in the controls (black column), indicating that Nutlin-3 alone can 
increase p53 expression. The p53 expression in cells treated with bleomycin and Nutlin-3 
(yellow column) is higher than for bleomycin treatment alone (green column), and the 
difference is most distinct after 48 hours. The p53 expression is higher in PCI treated cells 
(light blue column) than PDT treated cells (dark blue column) and the difference is most 
distinct 24 hours post light. The p53 expression was higher in the PDT and PCI treated cells 
that received Nutlin-3 treatment (pink and grey column respectively) than the cells receiving 
PDT and PCI treatment alone 48 hours post light. It appears that PCI treatment induces the 
highest expression of p53 8, 24 and 48 hours post light. PDT results in higher levels of p53 
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than bleomycin 8 and 24 hours post light, whereas after 48 hours bleomycin treatment gives a 
great increase in p53 expression higher than PDT.  
 
 
Figure 3.10: Expression of MDM2 in SJSA-1 cells after PDT, PCI and BLM treatment in the absence or 
presence of Nutlin-3. The results were normalised with respect to total γ-tubulin, relative to untreated cells. The 
figure shows the result from one experiment.  
 
3.4.2 MDM2 
The differences in expression of MDM2 (figure 3.10) show two tendencies. In bleomycin 
(green column) and untreated cells (black column) the level of MDM2 decreased when 
Nutlin-3 was added, while in PDT and PCI treated cells (dark blue and light blue column 
respectively) it increased after Nutlin-3 treatment. The expression of MDM2 is higher after 
24 hours than 8 and 48 hours post light for all treatments. The MDM2 level was lower than in 
the control for many of the samples, and 48 hours post light all the samples expressed less 
MDM2 than the control. 
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Figure 3.11: Expression of p21 in SJSA-1 cells after PDT, PCI and BLM treatment in the absence or presence 
of Nutlin-3. The results were normalised with respect to total γ-tubulin, relative to untreated cells.  The figure 
shows the result from one experiment.  
 
3.4.3 p21 
To study the effect of Nutlin-3 treatment, the expression of downstream targets of p53 was 
measured by western blotting. An increase in p53 activity following an inhibition of the 
MDM2-p53 interaction may lead to increased expression of p21. For all treatments, the 
expression of p21 was considerably higher when Nutlin-3 was added (figure 3.11). The level 
of p21 increased 8 hours after light, and then decreased, indicating that the transcription of 
p21 is initiated ≤ 8 hours post light. The expression of p21 was higher in the PCI treated cells 
(light blue and grey column) than for the other treatments 8 to 48 hours post light. The 
expression of p21 is higher in the PDT treated cells (dark blue and pink columns) than the 
bleomycin treated cells (green and yellow columns) 24 hours post light, while 8 and 48 hours 
post light the expression in the bleomycin treated cells are slightly higher. The p21 levels in 
the cells treated with only Nutlin-3 (red columns) are higher than in the control (black 
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column) supporting the observation in 3.4.1 that Nutlin-3 alone can activate the p53 pathway, 
thereby inducing expression of the downstream target p21.  
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Figure 3.12: Expression of MDM2 in SJSA-1 cells after PDT, PCI and BLM treatment in the absence or 
presence of Nutlin-3. The results were normalised with respect to total γ-tubulin, relative to untreated cells. The 
figure shows the result from one experiment.  
 
3.4.4 Bax 
In this experiment, the medium in the dishes was removed before the monolayer was lysed. 
Any cells detached from the surface of the dish are therefore not included in this analysis. 
There is reason to believe that it might have had a significant impact on the expression of Bax 
since the treatments with the greatest loss in viability was observed with more cells detached 
from the surface of the dish, and may be apoptotic cells.  
The expression of Bax appears to be higher in the PDT and PCI treated cells treated 
with Nutlin-3 than those not treated with Nutlin-3 (figure 3.12). The cells receiving 
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bleomycin treatment or no treatment did not show a clear correlation between Nutlin-3 
treatment and Bax expression. The Bax level appears to be higher 24 hours post light than 8 
and 48 hours post light. 
 
3.5 Cell cycle analysis 
The cell cycle distribution of SJSA-1 cells after PDT and PCI treatment with or without 
Nutlin-3 was analysed using flow cytometry. In 25 cm
2
 flasks, 165 000 – 320 000 cells per 
flask were seeded and treated according to the PDT and PCI protocols. The PDT and PCI 
treated cells were incubated with 0,2 μg/ml TPCS2a for 18 hours before the PCI and BLM 
cohorts were incubated with 0,1 IU/ml bleomycin for 4 hours. Following the 4-hour chase, 
the PDT and PCI cohorts were illuminated for 160 seconds. From 4 hours before light until 
harvest half the cells were treated with 500 nM Nutlin-3. The cells were harvested 2 hours 
and 20 hours post light and prepared for analysis according to the flow cytometry protocol.  
 When genetic material is damaged, delay in cell cycle progression facilitates DNA 
repair and ensures genetic stability. The cell cycle checkpoints monitor the integrity and the 
replication status of the genome, and prevent cells with damaged DNA from entering the next 
phase in the cell cycle. The ability of the checkpoint to inhibit entry into S phase is closely 
related to the tumour suppressor p53 [18]. In cells with non-functional p53, due to mutations 
or MDM2 amplification, the cell cycle checkpoints will not function properly, and cells with 
damaged DNA might progress in the cell cycle.  
The impact of adding Nutlin-3 on progression in the cell cycle in SJSA-1 cells was 
studied using flow cytometry. The cells harvested 2 hours post light showed very small 
differences in cell cycle (results not shown). In the samples harvested 20 hours post light 
(figure 3.13), greater differences were seen. In the PCI samples (figure 3.13D), a greater 
proportion of the cells treated with 500 nM Nutlin-3 were in G1 and G2 phase and fewer were 
in S phase than the cells only receiving PCI treatment. For the other treatments (figure 3.13A-
C) the S-phase fraction appears to be approximately the same in the absence or presence of 
Nutlin-3, but there are more cells in G1-phase after Nutlin-3 treatment than for the 
corresponding treatment without Nutlin-3.  
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Figure 3.13: Cell cycle phase distribution 20 hours post light in SJSA-1 cells who received no treatment (A), 
0,1 IU/ml bleomycin (B), PDT (C) or PCI with 0,1 IU/ml bleomycin (D) with or without 500 nM Nutlin-3. All 
figures show a representative result from a single experiment. 
 
 
  
NT Nutlin
D
is
tr
ib
u
ti
o
n
 (
%
)
0
20
40
60
80
100
G1 
S 
G2 
BLM BLM + Nutlin
D
is
tr
ib
u
ti
o
n
 (
%
)
0
20
40
60
80
100
G1
S
G2
PDT PDT + Nutlin
D
is
tr
ib
u
ti
o
n
 (
%
)
0
20
40
60
80
100
G1
S
G2
PCI PCI + Nutlin
D
is
tr
ib
u
ti
o
n
 (
%
)
0
20
40
60
80
100
G1
S
G2
 49 
  
 50 
4 Discussion 
 
4.1 Background 
The tumour suppressor p53 plays an essential role in protecting the cell from malignant 
transformations by inducing cell cycle arrest and apoptosis. In response to stress, a decrease 
in MDM2 protein levels and/or its activity and the interaction between MDM2 and p53 leads 
to p53 stabilisation and subsequently activation of the p53 pathway [9]. This reduction of 
MDM2 is crucial for p53 to exert its tumour suppressor activity.  
 With approximately 50% of all human malignancies containing mutations in the p53 
gene [6], restoration of the p53 pathway is an attractive target for improving cancer therapy. 
There are several strategies for reactivating p53 in cancer cells, including adenovirus vector-
mediated p53 transduction, p53 activation by regulatory proteins that modify p53, and 
reactivation of mutant p53. A strategy of activating wild-type p53 in MDM2
Ampl
 cells targets 
the interaction between p53 and its negative regulator MDM2 [68]. In this study, the latter 
approach was investigated through the small molecule inhibitor of the MDM2-p53 
interaction, Nutlin-3.  
 
4.2 Nutlin-3 
Nutlin-3 inhibits the MDM2-p53 interaction by displacing p53 from its complex with 
MDM2, thereby restoring the p53 pathway in vitro and in vivo [2]. Because of this direct 
inhibitory effect, Nutlin-3 can fully compensate for defects in the upstream p53 signalling. 
This requires intact downstream signalling, and it is therefore important to know of any 
aberrations in the p53 pathway, and to identify the tumours carrying them [69]. Nutlin-3 has 
been shown to be effective against a variety of cancer cells with wild-type p53, including 
neuroblastoma, retinoblastoma, osteosarcoma and leukemia [33]. In p53
Mut
 and p53
Null
 cell 
lines, Nutlin-3 has not shown any effect on growth and viability, suggesting that its activity is 
solely derived from activation of p53
Wt
 signalling [1, 13]. In several tumour cell lines an 
increase in p21 mediated cell cycle arrest were seen upon p53 activation, but only a marginal 
increase in apoptosis, indicating that defective apoptotic signalling is not infrequent in solid 
tumours [35]. Activation of the p53 pathway with Nutlin-3 is a promising approach in cancer 
therapy, but further studies are needed to investigate its full therapeutic potential. 
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4.3 Cell lines 
As a model for p53
Wt
 and MDM2
Ampl
 cells, the osteosarcoma cell line SJSA-1 was chosen 
[70]. This cell line has already been subject to extensive research on the effects of Nutlin-3 
treatment, both as monotherapy and in combination with established cancer therapies [1, 35, 
71-73]. The cell line SJSA-1 was used as a model for cancer cells retaining wild-type p53, 
but have non-functional p53 due to overexpression of MDM2. The hypothesis is that this cell 
line will respond well to treatment with Nutlin-3. 
 In addition to the SJSA-1 cell line, two other cell lines were used in this study. The 
leiomyosarcoma cell line SK-LMS1 express p53
Mut
 and low levels of MDM2 [70]. Studies 
have shown little or no effect on cell cycle arrest and apoptosis of Nutlin-3 in cell lines with 
mutant p53, and SK-LMS1 was therefore chosen as a negative control. The third cell line 
included in this study was the uterine sarcoma cell line MES-SA. MES-SA express p53
Wt
 and 
unknown levels of MDM2 [74].  
 
4.4 Effect of Nutlin-3 on cell survival 
The response to PDT and PCI treatment with saporin and bleomycin was investigated in SK-
LMS1, MES-SA and SJSA-1 cells (figure 3.3-3.5). All cell lines responded well to treatment, 
and a greater loss of viability was seen after PCI treatment compared to PDT. These 
experiments were only done once, and should be repeated to confirm and possibly quantify 
the differences.  
 To investigate the effect Nutlin-3 treatment has on cell survival after PDT and PCI 
treatment, the same experiments was carried out in the SJSA-1 cell line with half the cells 
being treated with 500 nM Nutlin-3. In the cells treated with PCI of saporin there were very 
small differences in loss of viability between the SJSA-1 cells that were incubated with 
Nutlin-3 and those that were not (figure 3.7B-D). In the PDT treated cells (figure 3.7A) there 
appears to be an increased loss of viability in the Nutlin-3 treated cells, and this difference is 
more distinct than for the PCI treated cells. After PCI of bleomycin in SJSA-1 cells, only a 
slight difference in loss of viability is seen between the cells treated with Nutlin-3 and those 
only receiving PCI treatment, as measured by the clonogenic assay (figure 3.8B). It appears 
to be a greater difference in the PDT treated cells (figure 3.8A), but this difference is smaller 
than for PDT in the presence or absence of Nutlin-3 when measured by the MTT assay 48 
hours post light (figure 3.7A).  
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In 2012, Wang et al. studied the effect of Nutlin-3 on cell viability of the p53
Wt
 
osteosarcoma cell line U-2 OS. Nutlin-3 inhibited cell growth in a time- and dose-dependent 
manner, with concentrations of 2-10 μM inducing a gradual effect on cell growth [2]. In this 
thesis, a concentration of 0,5 μM Nutlin-3 was utilised in all experiments with the SJSA-1 
cell line. This concentration did induce p21 expression (figure 3.11) thus having an impact on 
cell cycle progression, but it may not have been sufficient to induce significant effects on 
colony formation. Cell cycle arrest may affect the result of the MTT assay, but a mere delay 
in cell cycle progression does not necessarily reduce the clonogenicity of the cells and may 
therefore not give visible impact on viability when measured with the clonogenic assay. This 
might explain the above-mentioned difference in viability measured by MTT (figure 3.7A) 
and the clonogenic assay (figure 3.8A) after PDT.  
 
4.5 Effect of Nutlin-3 on protein expression 
To investigate the effect treatment with Nutlin-3 had on expression of p53 and p53 target 
genes, protein expression was measured with western blotting. The p53
Wt
 MDM2
Ampl
 cell 
line SJSA-1 was chosen for these experiments, and the aim was to compare the levels of p53, 
MDM2, p21 and Bax in the cells after PDT, PCI treatment, bleomycin treatment or no 
treatment with or without Nutlin-3. The experiment was done only once, so the results should 
be considered indicative. 
 The protein analysis included only those cells still attached to the surface of the wells 
at the time of harvest. In several of the wells, in particular those receiving PDT and PCI 
treatment, a large number of cells were detached from the surface and were dispersed in the 
medium. The medium was aspirated off prior to cell lysis, and these cells were therefore not 
included in the sample preparation. This may have affected the result of the measurement of 
the protein expression, and for future experiments, the cells dispersed in the medium should 
be included in the analysis.   
 
4.5.1 Effect on p53 expression 
The effect of Nutlin-3 on p53 protein expression has been studied in several different cell 
lines. Ohnstad et al. [1] showed elevated levels of p53 in the p53
Wt
 cell lines SJSA-1, T778 
and U2OS after treatment with the IC50 dose of Nutlin-3 for 24 hours compared to the 
control. The largest difference was seen in the MDM2
Ampl
 cell lines SJSA-1 and T778. The 
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p53
Mut
 cell line RMS13 and the p53
Null
 cell line SaOS-2 did not respond to treatment with 
Nutlin-3.  
 In this study, all treatments triggered an increase in p53 expression (figure 3.9). 
Ohnstad et al. reported higher expression of p53 in SJSA-1 cells treated with Nutlin-3, and 
that the cells receiving treatment with Nutlin-3 in combination with cisplatin had the highest 
expression of p53, indicating an additive effect. The same additive effect was seen in this 
study. In general, the cells treated with Nutlin-3 expressed more p53 than the cells that were 
not treated with Nutlin-3. The cells receiving only Nutlin-3 treatment expressed more p53 
than the controls, indicating that Nutlin-3 alone can induce p53 expression. The difference 
increased with number of hours the cells were incubated with Nutlin-3, showing that the 
number of hours the cells are treated with Nutlin-3 has an impact on p53 expression. This is 
consistent with publications reporting a time-dependent activation of p53 by Nutlin-3 [75, 
76]. 
The expression of p53 is highest 8 hours and 48 hours post light, which is consistent 
with results previously reported by Tovar et al. [35]. The rise in p53 level 8 hours post light 
may originate in the PDT effect, while the second rise may be due to the effect of bleomycin. 
Bleomycin is a slow acting substance, and may therefore require more time to induce an 
increase in the p53 expression. After 48 hours the p53 expression in the cells treated with 
bleomycin with or without Nutlin-3 is considerably higher than at 8 and 24 hours indicating 
that the rise in p53 level occurs later after treatment with bleomycin than after PDT and PCI 
treatment. 
The PCI treated cells express more p53 than the other cells 8 to 48 hours post light. 
The difference is most distinct after 8 hours and this may be due to both the PDT effects and 
the effects of the bleomycin released in the cytosol upon light exposure.   
 
4.5.2 Effect on MDM2 expression 
MDM2 regulates p53 through an autoregulatory feedback loop in which both proteins 
mutually control their cellular level. Increased levels of p53 activate mdm2 gene 
transcription, leading to elevated levels of MDM2. In turn, MDM2 binds to p53 and 
negatively regulates its stability and activity. This feedback loop keeps p53 under tight 
control and prevents it from inducing cell cycle arrest and apoptosis in normal proliferating 
cells [12].  
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 When the interaction between p53 and MDM2 is inhibited by Nutlin-3, p53 is 
relieved from the negative control and the cellular level of p53 may rise. The increase in p53 
will subsequently activate MDM2 expression, leading to accumulation of MDM2 protein 
[12]. Vassilev et al. showed in 2004 that the level of p53, MDM2 and p21 in the p53
Wt
 cell 
line HCT116 increased in a dose-dependent matter after treatment with Nutlin. In contrast, 
the p53
Mut
 cell line SW480 showed high basal levels of p53, but no detectable MDM2 or p21 
[13]. 
 In this study, the expression of MDM2 was measured in the SJSA-1 cell line 8, 24 
and 48 hours post light (figure 3.10). The level of MDM2 appears to be highest 24 hours post 
light. This increase might be a result of the increase in p53 8 hours post light (figure 3.9). The 
treatment resulting in the highest MDM2 level is bleomycin treatment. PCI treatment induced 
MDM2 expression more than PDT and the difference was most distinct 24 hours post light. 
For cells receiving bleomycin treatment, the Nutlin-3 treated cells expressed less MDM2 than 
the cells receiving bleomycin alone. This difference is most distinct for the cells harvested 
after 8 hours, while after 48 hours the difference is diminutive. We would expect higher 
levels in the Nutlin-3 treated cells since these cells expressed more p53 than the cells treated 
with bleomycin alone. In both PDT and PCI treated cells, Nutlin-3 treatment resulted in an 
increase in MDM2 expression. This correlates with the higher levels of p53 measured in the 
cells receiving Nutlin-3 treatment in addition to PDT and PCI treatment. 
The measured expression of MDM2 was lower than in the control for many of the 
samples, and this does not match the results seen in a number of publications [1, 33, 35, 77]. 
In addition, Ohnstad et al. reported that Nutlin-3 treatment significantly induced MDM2 
expression in SJSA-1 compared to control, which does not correlate with the results in this 
study. The experiment should therefore be repeated to confirm or refute the results in this 
study.  
 
4.5.3 Effect on p21 expression 
With its ability to induce cell cycle arrest, p21 is an important protein in the cells response to 
DNA damage [18]. Increased levels of p53 can activate the transcription of the cyclin-
dependent kinase inhibitor p21, thereby blocking cell cycle progression and if deemed 
necessary induce apoptosis [78]. Measuring the expression of p21 is therefore a useful tool to 
study the effect of Nutlin-3 treatment. 
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 Ohnstad et al. [1] studied the expression of p21 in 5 different cell lines after treatment 
with Nutlin-3. In the p53
Wt
 cell lines SJSA-1, T778 and U2OS the level of p21 was elevated 
in the cells receiving Nutlin-3 treatment compared to control. The difference was particularly 
profound in the MDM2
Ampl
 cell line SJSA-1. In the p53
Mut
 cell lines, there was no apparent 
difference in the p21 expression in the Nutlin-3 treated cells and the controls.  
 The results from this study indicate that the expression of p21 is considerably higher 
in the cells receiving Nutlin-3 treatment (figure 3.11). This is a good indicator that Nutlin-3 
inhibits the p53-MDM2 interaction, thus allowing a raise in the p53 level with subsequent 
transcription of p21. The p21 level is higher 8 hours post light than 24 and 48 hours post 
light, indicating that the transcription of p21 is initiated ≤ 8 hours post light. This is 
consistent with the results of Ahmad et al. reporting that PDT significantly induced p21 
expression 3, 6 and 12 hours after treatment [79]. The expression of p21 is higher in the cells 
receiving PCI treatment than for any of the other treatments, especially 8 hours post light. 
This correlates with the expression of p53 (figure 3.9), which is higher in the PCI treated 
cells, indicating that PCI strongly activates the p53 pathway. The expression of p21 is higher 
in PDT treated cells than bleomycin treated cells 8 and 24 hours post light, while 48 hours 
post light the opposite is seen. These results also correlate with the expression of p53, which 
follows the same pattern.  
 
4.5.4 Effect on Bax expression 
The Bcl-2 family protein Bax is one of the main regulators of the mitochondrial pathway of 
apoptosis. Once activated, Bax will act as a direct activator of the apoptotic pore in the 
mitochondria, leading to cytochrome c release and controlled cell death [80]. Bax is a 
downstream p53 target, and an activation of p53 will potentially lead to increase in Bax. 
Studying the expression of Bax is therefore of great value when investigating the effect 
Nutlin-3 has on the induction of apoptosis. 
 Miyachi et al. reported in 2009 that Nutlin-3 treatment increased the mRNA levels of 
Bax by 1.3-fold to 2.5-fold in the three p53
Wt
 cell lines RMS-YM, Rh18 and RM2. In 
contrast, Nutlin-3 induced only a slight difference in the mRNA levels of Bax in Rh30 and 
RD cell lines with mutant p53 [33]. In 2012, Mochizuki et al. studied the effect of Nutlin-3 
on Bax expression and apoptosis. They reported a significant increase of Bax mRNA in the 
three p53
Wt
 feline lymphoma cell lines FT-1, FTG and MS4 upon Nutlin treatment that was 
not seen in the p53
Mut
 cell lines 3201 and MCC. These results were supported by a dose-
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dependent induction of apoptosis in the p53
Wt
 cells. In the p53
Mut
 cells, no increase in 
apoptosis was observed, even after incubation Nutlin-3 concentration as high as 20 μM [68].  
 In this study, the cells receiving Nutlin-3 treatment in addition to PDT and PCI 
treatment showed an increase in Bax compared to those not treated with Nutlin-3 (figure 
3.12). This correlates with the results in section 3.3.4 showing a greater loss of viability in the 
PDT and PCI treated cells incubated with Nutlin-3 than after PDT and PCI treatment alone. 
The expression of Bax is higher after PCI treatment than after PDT. This correlates with the 
results in section 3.3.2 where PCI of bleomycin induces a greater loss of viability than PDT. 
The Bax level appears to be higher 24 hours post light than 8 and 48 hours post light. As 
discussed above, the transcription of p21 is initiated ≤ 8 hours post light. It appears that the 
cells are given time to stop in the cell cycle and attempt DNA damage repair before apoptosis 
is eventually induced.  
One great weakness to these results is that the cells not attached to the surface of the 
wells were not included in the analysis. Early in apoptosis the cells round up and may detach 
from the surface and their neighbouring cells. It is therefore reason to believe that many of 
the apoptotic cells, expressing high level of Bax, were lost during sample preparation. This 
experiment should be repeated, including the cells dispersed in the medium.  
 
4.6 Cell cycle analysis 
p21 mediated induction of cell cycle arrest in response to stress is one of the key features of 
p53 as a tumour suppressor. p21 binds to and inhibits the kinase activity of the cyclin-
dependent kinases (CDKs) CDK1 and CDK2 leading to growth arrest mainly in the G1 phase 
of the cell cycle [81, 82]. This growth arrest gives the cells time to repair the DNA damage, 
or in the event of irreparable damage, apoptosis is induced [17]. Cell cycle analysis is a 
valuable tool in studying the effect Nutlin-3 has on the p53 pathway. 
 Several studies have looked into the cell cycle effect of Nutlin-3 in different cell lines. 
Miyachi et al. reported in 2009 that a 24-hour treatment with Nutlin-3 arrested the cell cycle 
of rhabdomyosarcoma cells with wild-type p53, decreasing the S-phase fraction from 30-40% 
to 5-20%. In contrast, Nutlin-3 had no effect on the cell cycle progression of Rh30 and RD 
cell lines with mutated p53 [33]. In 2012, Wang et al. reported that Nutlin-3 induced G1 
arrest in p53
Wt
 U-2 osteosarcoma cells in a dose-dependent way [83]. The study showed that 
treatment with 10 μM Nutlin-3 significantly increased G1 phase and decreased S-phase 
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fraction in U-2 OS cells but gave no significant increase in G1-phase fraction in p53
Mut
 cell 
line MG63 or p53
Null
 cell line SaOS2.  
 In this study, a cell cycle analysis of the p53
Wt
 MDM2
Ampl
 cell line SJSA-1 was 
carried out. The cells were treated with bleomycin, PDT or PCI of bleomycin with or without 
0,5 μM Nutlin-3. After 20 hours (figure 3.13), the PCI cells treated with Nutlin-3 appears to 
have a substantial decrease in the S-phase fraction and an increase in the G1-phase fraction. 
The S-phase fraction of these cells was substantially higher than measured in SJSA-1 cells 
treated with 10 μM Nutlin-3 by Tovar et al. in 2006 [35]. In this paper, Tovar et al. reported 
that Nutlin-3 induced p21 expression in a dose-dependent matter, which might explain the 
greater impact on cell cycle they reported. As previously seen in this study, Nutlin-3 induces 
expression of p21 through activation of the p53-pathway (figure 3.11). The expression of p21 
8 hours post light is substantially higher in the cells treated with PCI and Nutlin-3 than for 
any other treatment. This may explain the great difference in S-phase fraction between PCI 
treated cell in the presence or absence of Nutlin-3 that is not seen in any of the other samples.  
When the SJSA-1 cells were treated with PCI of bleomycin (figure 3.8), the presence 
and absence of Nutlin-3 had only limited impact on cell viability, as measured with the 
clonogenic assay. The expression of Bax after PCI of bleomycin did not show great 
differences in the presence or absence of Nutlin-3 (figure 3.12). The results in this study 
indicates that 500 nM Nutlin-3 triggers cell cycle arrest after PCI of bleomycin, but does not 
induce apoptosis to a great extent. When considering the dose-dependent effects of Nutlin-3 
on cell cycle and cell viability reported by Wang et al. [83], it may be wise to optimise the 
Nutlin-3 dose for future experiments both regarding the concentration of Nutlin-3 added and 
the timing of the treatment.  
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5 Conclusion 
 
In this study, the impact of Nutlin-3 on cell survival, cell cycle progression and expression of 
p53 and p53 downstream targets after PDT and PCI treatment was investigated. The results 
show that Nutlin-3 activated the p53 pathway inducing the expression of the p53 downstream 
targets MDM2, p21 and Bax in the p53
Wt
 MDM2
Ampl
 osteosarcoma cell line SJSA-1. 
Furthermore, the study showed that Nutlin-3 induces cell cycle arrest in the G1/S checkpoint 
in SJSA-1 cells after treatment with PCI of bleomycin. The impact of Nutlin-3 on cell 
survival after PDT and PCI of saporin and bleomycin is still not clear, but the results indicate 
that Nutlin-3 does have a negative impact on cell growth. Future work on different cell lines 
and optimisation of Nutlin-3 doses and timing needs to be done to better evaluate the 
therapeutic potential of Nutlin-3.  
 The present study suggest that the combination of Nutlin-3 and PCI treatment could 
be a promising therapeutic strategy for tumours with non-functional p53 due to 
overexpression of MDM2.  
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Appendix A 
 
Lysis buffer for SDS-PAGE 
10 µl NaF 200 mM in dH2O 
10 µl PMSF 200 nM in isopropanol  
10 µl activated Na2VO4 
20 µl β-glycerol phosphate 2 M in dH2O 
20 µl phosphatase inhibitor cocktail I (Sigma-Aldrich) 
20 µl phosphatase inhibitor cocktail II (Sigma-Aldrich) 
20 µl protease inhibitor cocktail (Sigma-Aldrich) 
Ad 2 ml sample buffer 
 
Sample buffer 
6,2 mM Tris-HCl 
2% (w/v) SDS (Bio-Rad) 
10% (w/v) glycerol (VWR) 
50 mM DTT (Sigma-Aldrich) 
0,01% bromphenol blue 
 
Transfer buffer 
3,75 g SDS 
15,1 g Trizma® Base 
71,4 g glycine 
1 L methanol (VWR) 
Ad 5 L dH2O 
 
10 x Running buffer pH 8,3 
10 g SDS 
30 g Trizma® Base (Sigma-Aldrich) 
144 g glycine (Sigma-Aldrich) 
Ad 1 L dH2O 
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1 x Running buffer 
100 ml 10x Running buffer 
Ad 1 L dH2O 
 
10 x TBS pH 7,6 
12,11 g Trizma® Base 
87,66 g NaCl 
Ad 1 L dH2O 
 
1 x TTBS 
100 ml 10x TBS 
100 ml Tween 20 (Sigma-Aldrich) 
Ad 1 L dH2O 
 
Separating gel with 12% acrylamide (1 gel) 
2,45 ml ddH2O 
1,9 ml 1,5M Tris-HCl pH 8,8 
75 µl 10% (w/v) SDS 
0,75 ml glycerol 
2,25 ml 40% Acrylamide/Bis solution (Bio-Rad) 
75 µl 10% ammonium persulfate (Bio-Rad) 
5 µl TEMED 
 
Stacking gel (1 gel) 
3,2 ml ddH2O 
1,25 ml 0,5M Tris-HCl pH 6,8 
50 µl 10% SDS 
0,5 ml 40% Acrylamide/Bis solution 
25 µl 10% ammonium persulfate 
5 µl TEMED 
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10% sodium dodecyl sulfate (SDS) 
10 g SDS 
Ad 100 ml dH2O 
 
0,5M Tris-HCl pH 6,8 
17,5 g Tris-HCl 
1,7 g Trizma® Base 
dH2O ad 250 ml 
 
0,5M Tris-HCl pH 8,8 
9,23 g Tris-HCl 
38,5 g Trizma® Base 
dH2O ad 250 ml 
 
5% non-fat dry milk solution 
5 g skimmed milk powder 
100 ml TTBS 
 
5% BSA solution 
5 g BSA (Sigma-Aldrich) 
100 ml TTBS 
 
TdT reaction solution (6 samples) 
0,96 µl TdT enzyme (Roche Applied Science, Indianapolis, IN, USA) 
24 µl TdT reaction buffer (Roche Applied Science) 
14,4 µl CoCl2 (25 mM) (Roche Applied Science) 
2,4 µl Biotin-16-dUTP (Roche Applied Science) 
2,4 µl DTT (10 mM) (Sigma-Aldrich) 
196 µl ddH2O 
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10 mM DTT 
15,425 mg Dithiothreiol (MW = 154,25 g/mol) (Sigma-Aldrich) 
10 ml dH2O 
 
Primary Ab for Flow Cytometry (6 samples) 
0,67 µl mouse α-γH2AX (Millipore) 
0,67 µl rabbit α-P-histone-H3 (Millipore) 
332 µl 5% non-fat dry milk in PBS 
 
Secondary Ab for Flow Cytometry (6 samples) 
6,67 µl goat α-rabbit-PE (Invitrogen/Life Technologies, Carlsbad, CA, USA) 
6,67 µl rabbit α-mouse-FITC (Dako, Glostrup, Denmark) 
0,83 µl Streptavidin-Cy5 (GE Healthcare) 
319,17 µl 5% non-fat dry milk in PBS 
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Appendix B  
 
Ladder for SDS-PAGE 
 
Substance: Produced by: Diluted in: Dilution: 2
•
 antibody: 
Kaleidoskop Bio Rad Lysis buffer 2:5 None 
Biotinylated ladder Cell Signaling Lysis Buffer 1:5 Anti-Biotin 
 
 
Primary antibodies used for immune detection in Western blotting 
 
1
•
 antibody: Produced by: Diluted in: Dilution: 2
•
 antibody: 
Anti-p53 (sc-6243) Santa Cruz  5 % milk 1:1000 Anti-rabbit 
Anti-p21 (sc-397) Santa Cruz  5 % milk 1:1000 Anti-rabbit 
Anti-MDM2 (ab38168) AbCam  5 % BSA 1:300 Anti-rabbit 
Anti-Bax (#2772) Cell Signaling  5 % BSA 1:1000 Anti-rabbit 
 
 
Secondary antibodies used for immune detection in Western blotting 
 
2
•
 antibody: Produced by: Diluted in: Dilution: 
Anti-biotin (#7075) Cell Signaling 5 % milk 1:1000 
Anti-rabbit (#7074S) Cell Signaling 5 % milk 1:5000 
 
 
 
